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Abstract 
It is known that 10- 28% of breast fed infants will develop iron deficiency (ID; serum 
ferritin s 12 ~g/L or Hgb s 110 g/L + Hct s 33% or MCV s 75 fl) by 6 months of age. Iron 
deficiency anaemia will effect 1 0 - 15% of the exclusively breast fed population by 6-months of age 
(IDA; Hgb s 110 g/L +serum ferritin s 12~g/L or Hct s 33% and MCV s 75 fl) . ID severe enough 
to cause anaemia has been proven to be a factor in delayed cognitive and psychomotor 
development. We initiated a randomized double blind clinical trial to investigate the effects of 
supplementing breast fed infants with iron and its effects on the incidence of ID and IDA (7.5 mg 
FeS04/day). Supplementation was between 1 to 6-month, to a maximum of 150 days. Further 
investigation into whether the supplement had any adverse effects on the antioxidant status, 
potential for oxidative damage and mineral absorption of the infants was also carried out. Our 
findings have shown that ID can affect as high as 55% of infants (p<0.02). Iron supplementation, 
7.5 mg FeS04/day, is high enough to demonstrate a difference in the haemoglobin concentrations 
(124+/-9.13 g/L vs. 116+/-6.68 g/L), hematocrit (0.352+/-0.029 vs. 0.333+/-0.019) and MCV 
(81.17+/-4.13 fl vs. 77.22+/-3.89 fl) compared to infants whom are not supplemented (p<0.05). 
While plasma ferritin concentrations did not differ between the two groups the infants receiving 
placebo had a significantly higher rate of decline in ferritin stores between 1 and 3.5 months than 
did infants who were supplemented (-82+/-54 1-1g/L vs. -139+/-84 1-19/L). This level of iron 
supplementation does not appear to affect the antioxidant response of erythrocyte superoxide 
dismutase or catalase nor does it change the total antioxidant power of the infant plasma (FRAP). 
Plasma mineral concentrations were normal for all infants but plasma zinc concentrations 
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significantly increased between the 3.5 and 6-month blood samples (p<0.05), with not enough data 
to explain. Positive correlations exist between the infant 1-month haemoglobin and 3.5 and 6-
month plasma ferritin concentrations, which may prove useful as a predictor of iron stores for 
infants who are exclusively breast fed. Breast milk iron concentrations were measured at 1 and 
3.5-months (0.47+/-0.14 mg/L to 0.76+/-0.40 mg/L at 1-month; 0.29+/-0.13 mg/L to 0.78+/-0.36 
mg/L at 3.5-months) by three separate techniques, direct GFAAS, methods of addition GFAAS and 
FAAS. While all three methods produced values that are in the reported range for human breast 
milk iron concentrations the direct GFAAS seems to have been validated by reports in literature 
and the methods of addition GFAAS as a simple, sensitive and reliable technique. Maternal 
haemoglobin at delivery was also examined as a predictor of breast milk concentrations and infant 
haemoglobin at 1-month but no relationships were seen between these variables. In all it appears 
that iron supplementation (7.5 mg Fe/Day) will improve the iron status of exclusively breast-fed 
infants without risk of impaired mineral absorption or oxidative damage. The iron status of 
exclusively breast-fed infants appears to be poor. There is a need for better screening or 
supplementation of these infants in order to prevent this deficiency. 
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Chapter 1: Literature Review 
1.1 Iron Deficiency 
Iron deficiency (I D) is a lack of or shortage of iron in the body usually caused by a 
nutritional deficiency. This is the pool of iron the body draws upon for metabolic processes such as 
the production of haem for red blood cells, enzymes and co-factors as well as fatty acids and other 
lipids. Once iron stores are depleted there is an appreciable decline in each of these processes as 
the different systems begin to compete for iron. The anaemia that may result is a clinical 
manifestation of prolonged iron deficiency. The progression from 10 to IDA in the infant occurs 
rapidly due to the increased metabolic iron requirement for proper growth and the increasing size 
of the infant. Iron is required for maintaining existing cells and for cell proliferation throughout this 
period of rapid growth. Symptoms of iron deficiency anaemia (IDA) include pallor, decreased 
vitality, dizziness and digestive problems. Iron deficiency during periods of infantile growth can 
cause damage or developmental set backs beyond those manifested in adults. Proper 
neurological and visual development requires adequate iron for proper oxygenation of tissue and 
for the production of long chain fatty acids (Larkin and Rao, 1990). As well, the infant has a rapidly 
expanding blood volume requiring an abundance of iron for the production of haem and red blood 
cells. Infants are therefore forced to draw heavily upon the stores laid down in utero depleting 
them by 6-months of age. Four - six month old infants can cope with this stress provided they are 
weaned with foods containing iron but not all exclusively breast fed infants are able to manage in 
this manner (Dewey et al, 1998). For 10-20% of this exclusively breastfed population, IDA is 
inevitable and will potentially be accompanied by other undesirable consequences. Further 
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discussion of the criteria of ID and IDA will follow. Generally, ID it is characterized by low iron 
stores, diagnosed using a complete blood count (CBC) which reports the number of blood cells as 
well as the relative size and amounts of constituents such as haemoglobin, demonstrating low 
haemoglobin and low serum ferritin usually quantified by ELISA tests. 
1.1.1 World Wide Perspective on Iron Deficiency 
Today ID is one of the world's most common nutritional deficiencies and is regarded as 
one of the major health problems worldwide despite near elimination of the conditions in the 
developed world (DeMaeyer et al, 1985; WHO, 2001 ). The major causes of iron deficiency and the 
resulting anaemia worldwide are inadequate dietary sources, low bioavailability and parasitic 
infection (WHO, 2001 ). While Canada and the rest of the developed world have a far lower 
incidence of iron deficiency anaemia compared with less developed countries, it is still the leading 
cause of anaemia in all age groupings (WHO, 2001 ). Specific sub-populations in our country suffer 
from iron deficiency anaemia. Women of menstruating age, the elderly and the malnourished 
commonly suffer from this disorder but breast fed · infants appear to be at the greatest risk of 
developing iron deficiency. Supplemental iron, both medicinal and dietary, is the most common 
practice used to avoid and treat the condition in all groups affected. 
1.1.2 Iron Status of Infants Through the First Year of Life 
Some investigators believe that the endowment of iron and status of the infant at birth is 
enough to carry them through the first six months with the introduction of solid foods providing 
adequate sources of iron for the first year of life. Other investigators believe that not all exclusively 
breastfed infants are protected from IDA with the iron stores laid down at birth. Regardless of the 
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arguments, data over the past number of years, demonstrates a clear picture for infants with regard 
to iron status. 
Between 20 - 25% of infants worldwide suffer from iron deficiency anaemia and an even 
higher number suffer from iron deficiency without anaemia (DeMaeyer et al, 1985; WHO, 2001 ). 
Therefore it may be taken for granted that breastfed infants are receiving adequate amounts of iron 
from dietary sources. Several studies worldwide have demonstrated the incidence of ID and IDA in 
the infant population of the developed world (Figure 1.1 ). While not all studies were performed on 
exclusively breastfed infants, those that were demonstrated an incidence ranging between 10-
28% (figure 1.1) including 10 - 15% of exclusively breastfed Canadian infants suffering from iron 
deficiency anaemia within the first year of life (Innis et al, 1997; Friel et al, 1997). Iron deficiency 
was seen in otherwise healthy infants and would most likely not have been diagnosed so early 
without the scheduled screening provided in these studies. Differing criteria from study to study 
suggest a need to define exactly what criteria are used to determine the iron status of infants. 
1.1.3 What Constitutes Iron Deficiency and Iron Deficiency Anaemia 
A clear definition of ID and IDA depends on the circumstances under which the disorder is 
being investigated. Clinically, IDA can be detected from a complete blood count. Haemoglobin, 
hematocrit and mean corpuscular volume are the measures used to identify IDA. For Canadian 
infants the clinical anaemia cut-off values for haemoglobin is a value less than 110 g/L, a 
hematocrit is less than 33% and a mean corpuscular volume less than 75 fl. The WHO has 
established the cut-off values for haemoglobin and hematocrit at 110 g/L and 33%, respectively as 
the worldwide standard for identifying IDA (WHO, 2001). These haematological cut-offs are 
accurate for identifying IDA when other types of anaemia are ruled out. 
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Other types of anaemia have to be ruled out when making the diagnosis of IDA. A factor 
to consider in anaemia of subjects from African descent is the sickle cell trait. The anaemia 
resulting from the thalassemia trait is most common in subjects of Mediterranean descent. As well 
recent infections an infant may have had need to be considered, as they too will produce 
anomalous haematological results. As well microcytic anaemia, vitamin 812 (pernicious anaemia) 
folate deficiency and lead poisoning have to be ruled out for the diagnosis of IDA. Sickle cell is 
characterized by the crescent shaped red blood cell, infection is characterized by an abnormal 
haemoglobin value but normal MCV and RDW values while thalassemia is characterized by low 
MCV and normal ROW (Bogen et al, 2001). Microcytic anaemia is defined by a MCV less than 
70 fl with no other abnormal indices. While clinicians use these definitions to confirm the diagnosis 
of the condition, these criteria are not the only biochemical aspects used by researchers 
investigating IDA. There are a variety of measures commonly used by researchers to determine 
whether subjects are iron deficient, anaemic or both. 
Other researchers use a variety of methods to characterize subject iron status when 
investigating iron deficiency. Researchers, like clinicians, use the haemoglobin, hematocrit, MCV 
and other measures determined by a CBC when diagnosing ID and IDA. However, with the advent 
of the immunoassay there are commercially available kits to elucidate nearly all human proteins 
and receptors. Serum or plasma ferritin and transferrin receptors are commonly used when 
defining iron storage status (Sweet et al, 2001; Domell6f et al, 2001 ; Guldholt et al, 1991 ). Serum 
ferritin is the main storage iron storage protein in the human body. Ferritin stores iron in an 
inactive form and releases when signalled by cells throughout the body. Serum ferritin less then 
12 ).!g/ml is accepted as being characteristic of server iron deficiency with less then 20 ).!g/ml is 
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borderline iron deficient (Glassman, 1997). Serum transferrin and transferrin receptor are also 
useful measures of iron status. Serum transferrin less then 16% saturation is characteristic of 
severe anaemia and transferrin receptor will be high in cases of iron deficiency but the absolute 
values are not clearly defined due to differences in methods and lack of a useful standard (WHO, 
2001 ). Erythrocyte protoporphyrin (EPP) has also been used as an indicator of iron status 
(Domell6f et al, 2001). EPP will increase, as the production of haem is limited and will correlate to 
decreasing ferritin stores. EPP will also increase in cases of haemolytic anaemia and lead 
poisoning, therefore should not be used in areas with high prevalence of these conditions. 
Classification of iron status using criteria other than the more common, such as Hgb and 
other haematological values, make it difficult to compare results. The haemoglobin cut-off value 
varies between 95- 110 g/L, serum ferritin between 10-12 J.!QIL, hematocrit between 30-33%, 
MCV between 70- 75 fl, erythrocyte protoporphyrin usually >120 mg/L, transferrin saturation 
between 10 - 16% or lower and serum transferrin receptor usually >4.4 mg/L (Kim et al, 1996; 
Domell6f et al, 2001 ; L6nnerdal et al , 1994; Arvas et al, 2000; Willows et al, 2000; Morley and 
Lucas, 1999; Male et al, 2001; Pizarro et al, 1991; Harding et al, 2001 ). Not all researchers use all 
the indices listed above and not all use them consistently. Upon careful review it appears that the 
most widely used indicators iron status of infants would be the Hgb, MCV and plasma ferritin . 
These indicators are useful both to the clinician and the researcher as they are easily obtainable 
and comparable. The other indices (hematocrit, erythrocyte protoporphyrin, transferrin saturation 
and serum transferrin receptor) help when no clear determination can be drawn from the other 
indices if they are available. 
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Figure 1.1 Summary of findings on the prevalence of iron deficiency and iron deficiency anaemia within 
the infant population. t Indicates prevalence of iron deficiency and iron deficiency anaemia within 
exclusively breast-fed infant subjects. 
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1.1.4 Infant Iron Requirements and Absorption in the First Year of Life 
Samuel Farnan (1993) estimates to prevent the depletion of iron stores at birth, the Infant 
must absorb 0.55-0.75 mg iron/day from dietary sources. This amount will allow the infant to 
meet its developmental needs in the first year of life. This estimate is based on the allocation of 
iron at birth (birth weight of 2.5-3.5 kg) and the desired allocation for a 12-month old infant 
weighing 10.0- 10.5 kg. While this is not a challenge for infants consuming iron-fortified formulas 
(12mg iron/L), the exclusively breastfed infant cannot achieve this goal consuming breast milk 
alone. 
Iron concentrations for human breast milk are reported to be between 0.27- 0.90 mg/L 
(Casey, 1996). The concentration of iron in colostrum is higher than in mature milk but most milk 
consumed by infants is mature milk. Infants would be required to consume at least one litre per 
day of human milk and have an absorption efficiency of 100% in order to meet their estimated 
needs. The actual amount of iron that an infant in the first 6 months will obtain daily is more likely 
to be in the range of 0.09- 0.23 mg, assuming an absorption efficiency of 50% and a consumption 
of 650 ml of milk daily (Farnan, 1993; Casey, 1996). There is confusion regarding the actual 
absorption efficiency of infants with regard to iron from breast milk. McMillan and associates 
(1977) estimated absorption to be at 50% based on adult models. Saarinen and Siimes (1979) 
reported an efficiency of 70% for breast milk and 10% for formula. Until recently, 50% absorption 
of iron from human breast milk has since been assumed to be the standard absorption level 
accepted by most investigators in the field (Garry et al, 1981; McMillan et al, 1977). 
More recently it has been reported that the absorption of iron from dietary breast milk is 
between 12% and 20% (Davidsson et al, 1993; Abrams et al, 1996, Domell6f et al, 2002). Newer 
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methodologies and refined techniques in measuring iron turnover in infants have lead to a more 
conservative view as to the amount absorbed from human breast milk. Iron absorption is not 
constant and different factors will affect the amount of iron absorbed. For example, the presence 
of lactoferrin appears to lower the mean dietary absorption of iron to 12% from 20% in lactoferrin 
free milks (Davidsson et al, 1993). In addition, duel-tracer stable isotope experiments demonstrate 
that supplemental iron is better absorbed during a feed rather than between feeds, 15% versus 
11% respectively (Abrams et al, 1996). Most recently Domellof (2002) and associates have 
measured the absorption of iron from breast milk in 6-month exclusively breast fed infants who 
were either supplemented with ferrous sulphate or receiving a placebo. Absorption was found to 
be 16+/-11% at 6 months, with no differences between the group receiving iron supplements of 
those receiving the placebo. This study produced data on absorption similar to that found by both 
Davidsson et al and Abrams et al and demonstrates iron absorption from an exclusive breast milk 
diet to be low. These methods for the estimation of the absorption of iron from breast milk are 
limited as there has been no successful method to intrinsically label breast milk and measure 
absorption (Figueroa-Colan et al, 1989). There may or may not be higher absorption of iron from 
the bound sources which do not exchange with the added stable or radioactive isotopes of iron 
used in the previous methods. A fractional absorption of iron between 12 - 20% is a fair estimate 
based on the currently available values. 
In light of the latest figures pertaining to iron absorption from human breast milk it is clear 
that exclusively breastfed infants are at risk of developing iron deficiency during critical periods of 
growth in the first six months of life. Since many factors affect the absorption efficiency of both 
supplemental and inherent iron of the infant gastrointestinal tract careful review as to the proper 
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dosage and timing of supplementation is requi~ed . While supplemental iron presents the infant 
with the risk of oxidative damage, iron deficiency also exposes the infant to other sizable risks. 
These risks can be potentially damaging to an infants cognitive and psychomotor development with 
the effects lasting well into childhood (Lozoff et al, 2000). 
1.2 Effects of Iron Deficiency on Infant Development 
Infants suffering from IDA face challenges along the course of normal development, which 
may have long reaching effects. Key periods of development are jeopardized when infants have 
severe nutritional deficiencies. The blood cell production, central nervous system development, 
enzyme production, and susceptibility to illness and infection, all rely in part on proper iron status. 
1.2.1 Iron Containing Enzymes 
A number of proteins contain iron as an essential part of their biochemical function. Haem 
is one such protein, utilizing iron as an 02 carrier. Haem is required by haemoglobin for transport 
of 02 throughout the body. Haem is also a constituent of myoglobin, responsible for 02 
storage/transport in muscle tissue. An iron deficiency will lead to a decrease in oxygen carrying 
capacity due to the reduction in haem production. This is of particular importance in infants, given 
the rapid growth and expansion of blood volume during the first year of life. The mitochondrial 
system of electron transport is dependent on enzymes that contain haem such as cytochrome c 
oxidase. Proteins involved in oxidative and mitochodrial metabolism also require iron to work 
properly, i.e. non-haem containing proteins like glucose-6-phosphate dehydrogenase, 
dioxygenase, succinate dehydrogenase, NADH dehydrogenase and aconitate hydratase (Connors 
et al, 1996; Bradbury et al, 1997). Iron deficiency anaemia is characterized by decreased vitality, 
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which can be attributed to both the reduction in oxygen carrying capacity and the competition for 
iron in metabolic pathways. 
1.2.2 Central Nervous System 
It should be of particular interest that the normal human brain contains as much iron, on a 
weight basis, as the liver (Connors et al, 1996). Animal studies have shown that the distribution of 
iron in the brain, according to region, is relatively even as a function of protein or brain wet weight 
(Focht et al, 1997). However, brain iron is not evenly distributed among the cell types of the brain 
and CNS. Oligodendrocytes are the cell type most dependent on iron for proper function (Sanyal 
et al, 1996; Blissman et al, 1996). Given that the oligodendrocytes have the highest concentration 
of iron, CNS development and maintenance relies heavily on the presence of iron for myelination 
and oxidative metabolism (Connors et al, 1995; Bradbury et al, 1997). Iron is required by many 
enzymes such as glucose-6-phosphate dehydrogenase, dioxygenase, succinate dehydrogenase, 
NADH dehydrogenase, aconitate hydratase and cytochrome c oxidase (Connors et al, 1996; 
Bradbury et al, 1997). The oligodendrocytes rely on oxidative metabolism for energy production, 
which is partly responsible for the high iron content of the brain. 
The oligodendrocytes are cells that produce myelin for the CNS and again require high 
iron concentrations to facilitate the production of cholesterol and fatty acids (Larkin and Rao, 1990). 
Myelin is composed of 80% fatty acid, leading to the variety of enzymes found in oligodendrocytes 
that catalyze the production of fatty acids - haem containing enzymes (cytochromes) as well as 
fatty acid desaturases and lipid dehydrogenases and the cholesterol biosynthesis enzymes such 
as squalene oxidase (Connors et al, 1996; Larkin and Rao, 1990). High levels of ferritin in the 
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CNS counteract the destructive potential of this high level of iron surrounded by high levels of 
polyunsaturated fatty acids. The ferritin protein has a ferroxidase activity, which facilitates the 
oxidation of Fe2+ to the less reactive FeJ+. The protein then stores the iron as a ferric-
oxyhydroxyphosphate complex (Sanyal et al, 1996). 
Myelination has been referred to as a "once and for all" process given that the body does 
not have the capability for re-myelination after de-myelination has occurred (Larkin and Rao, 1990). 
While it is difficult to demonstration the effects of iron deficiency in the brain of human neonates, 
animal studies have shown the profound effects of the disorder during the critical period of 
myelination. Myelination begins about 10-days after gestation in rats; if an iron insult is inflicted on 
rats around this age the effects are devastating. A 30% reduction in myelin proteins has been 
reported as well as decreases to the total brain lipid in iron deficient neonatal rats (Larkin and Rao, 
1990). These findings are particularly alarming since there may be a large number of infants that 
are iron deficient who go undiagnosed until they are severely deficient. displaying clinical signs of 
anaemia. It is not possible to perform analysis of CNS tissue in iron deficient human neonates. 
However, the same conclusions regarding impaired myelination can be drawn from rat studies and 
applied to all mammalian development (Larkin and Rao, 1990). 
Altered nervous system responses have been reported in infants diagnosed with iron 
deficiency anaemia when compared to non-anaemic infants (Roncagliolo et al, 1998). Decreased 
auditory nerve responses and increased latency times between stimulus and neuron firing have 
been measured in IDA infants compared to non-anaemic infants and is suspected to be related to 
level of myelination (Roncagliolo et al, 1998). Like myelination, the brain's neurotransmitters are 
also affected by iron depletion. Decreases in the learning capacity, functionality of Dopamine D2 
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receptors and reversals of several circadian cycles (pain thresholds, motor activity etc) are 
common in iron deficient rats. These rat studies also show that the time required to learn a water 
maze increases over time as length of iron deficiency insult increases (Yehuda et al, 1990). These 
findings give weight to the argument that decreased CNS activity is a consequence of iron 
deficiency in neonates. 
1.2.3 Cognitive and Psychomotor Development 
Webb and Oski (1973) concluded the iron status of young children affected their 
performance on developmental tests. Webb and Oski tested school children aged 12 - 14 years 
using the Iowa Basic Skills testing, and demonstrated that anaemic children scored lower then iron 
sufficient children. Oski and Honig (1978) evaluated infants with iron deficiency anaemia and 
assessed the difference between scores when half the group had its iron replenished by medicinal 
intervention. Infants were tested for behaviour, cognitive and psychomotor development prior to 
and after iron therapy, using the Bayley Scales of Infant Development. Oski and Honig noted that 
the infants who were treated with iron and had their status corrected re-tested higher than they 
originally tested while iron deficient. Oski et al ( 1983) demonstrated iron deficient infants would 
score better on a developmental test after only 1 week of iron therapy. Oski and associates 
credited iron deficiency not the anaemia as causing the developmental impairments since one 
week of iron therapy is not sufficient to relieve an infant of anaemia (Oski et al, 1983). Oski and 
associates therefore concluded the iron deficiency rather than anaemia is the cause of the 
decreases seen in cognition and psychomotor development for iron deficient infants. While the 
conclusion as to the cause of the developmental differences may be correct it was not the reason 
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for the increase in test scores seen by Oski et al. A later study by Betsy Lozoff and associates 
would explain these observations. 
Lozoff and associates (1982) examined infants aged 6-24 months for impaired mental 
development as a function of iron status. The results supported those seen by Webb and Oski 
{1973) and Oski et al (1978) demonstrating infants with low iron status causing anaemia have 
' lower mental test scores than those with normal blood iron status. The study demonstrated that 
there is an appreciable decline in all infants test scores with age but the decline is far greater in 
those infants suffering from IDA. 
While there is not a wide range of research in the area of iron deficiency and cognitive 
development there appears to be a clear connection with low iron status and delayed cognitive 
development. Lozoff and associates (1987) then evaluated the differences between iron sufficient 
and iron deficient infants and the effects of short-term and long-term treatments on repeat tests of 
infant mental and psychomotor development. Her group also examined intra-muscular injections of 
iron and oral drops and their effectiveness after 1 week and 3 months. As seen in previously 
Lozoff and associates showed that infants with poor blood iron status score significantly lower than 
iron sufficient infants on indices of mental and behavioural development and have below normal 
psychomotor scores. No differences in the method of iron treatment (oral drops versus IM 
injection) were seen with respect to correcting iron status or increasing developmental test scores. 
Developmental testing after short-term iron treatment resulted in increases in all groups' test 
scores including the placebo. This increase in all groups demonstrates a test score increase 
independent of the iron status since the placebo group also increased. This effect has been 
referred to as the practice effect where familiarity with the test is the most probable reason for an 
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increase in the test score. This practice effect may have contributed to the increase in test scores 
seen in Oski et al (1978) study. Long-term treatment of 3 months, returning the blood indices to 
normal, results in increased mental test scores but the results do not reach the levels achieved by 
the previously iron sufficient group. This may be an indication that the iron insult has caused a 
permanent set back in mental development (Lozoff, 1987). 
Walter (1983) and his associates investigated the differences between infants suffering 
from iron deficiency anaemia, infants who were iron deficient and iron sufficient control infants in 
cognitive and psychomotor development and behaviour as measured by the Bayley Scales of 
Infant Development (BSID). Walter and associates used children of the same age, socio-economic 
and initial birth measurements. All children were 15 months of age and were recruited from an on 
going study on iron-fortified formula. They also examined the effects of short-term iron therapy on 
the anaemic and non-anaemic children. The iron treatment had significant effects on the anaemic 
children's Mental Development Index (MDI) and Infant Behaviour Record (IBR) scores while the 
control group, which also received the iron therapy, remained unchanged. The results showed a 
significant difference between the anaemic and iron sufficient groups MDI, with the anaemic 
children scoring lower but in the normal range for American children. The anaemic infants showed 
a significant difference in the "general emotional tone" portion of the IBR - indicating that the 
anaemic children were unhappier taking the test than the non-anaemic counterparts. They could 
see no initial difference in the Psychomotor Development Index (POl) between any of the groups. 
The group in this study with iron deficiency but no anaemia did not show any significant differences 
in the test-retest. The authors did note a sub-group within the iron deficient non-anaemic infants 
who did show a significant increase in MDI after iron therapy. The authors concluded anaemic 
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children score lower in BSID tests than those children who are iron sufficient. The increases seen 
in the test scores after the 11-day iron treatment are attributed to increases in attention span and 
cooperation in the infants not to an effect on the developing brain (Walter, 1983). 
Walter and his associates (1989) published a study, which compare iron status to BSID 
scores as well as the effect if any a short-term iron treatment of 1 0 days and a long-term iron 
treatment of 3 months had on the development scores. As shown previously, low haematological 
iron status resulted in lower BSID scores than infants that had normal haematological status (Oski 
and Honig, 1978; Walter et al, 1983). The authors conclude that the effect of short-term iron 
therapy is not the principle cause for the increases in the BSID test but increases are more likely 
attributable to a "practice effecf' of taking the tests. Iron therapy continued for 3 months after the 
initial re-test of BSID. Even after long-term iron therapy and return to normal haematological status 
the anaemic infants who previously tested lower did not approach the same scores as their iron 
sufficient counterparts in the control groups. The authors concluded iron deficiency during a critical 
developmental period may result in permanent impairment or a long-term set back in cognitive and 
psychomotor development (Walter et al, 1989). The level of iron deficiency that will cause these 
impairments is not known. 
Other researchers have published data, which indicate there are negative and potentially 
long-term effects of IDA. ldjradinata and Pollitt (1993) concluded that iron deficiency, severe 
enough to cause anaemia, would result to lower BSID scores for those children compared to the 
children who have normal iron status. The authors also conclude that long-term treatment is 
required to correct the differences in test scores (ldjradinata and Pollitt, 1993). Moffatt and 
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associates ( 1994) examined mildly anaemic infants and showed that mild anaemic was not enough 
to bring on the cognitive effects seen by other researchers. 
More recently Lozoff and associates ( 1998) concluded that infants who suffer from IDA 
and the resulting behavioural changes risk becoming functionally isolated from peers and overly 
dependent on caregivers. Lozoff and associates observed distinct behavioural differences 
between infants who were suffering from IDA compared to those who were not anaemic. 
Correction of the IDA does not always appear to correct all the behavioural differences observed 
(Lozoff et al, 1998). It has also been suggested that infants suffering from chronic IDA as infants 
will not perform as well academically or behaviourally as much as 10 years after the IDA insult 
(Lozoff et al, 2000). 
In summary, iron deficiency severe enough to cause anaemia is potentially hazardous to 
infants within the first year of life. Iron deficient infants suffering from anaemia consistently score 
lower in mental and physical development tests. The depletion of cellular iron to a point that 
causes anaemia may cause an insult which requires long term therapy to correct, and may put the 
child at a great disadvantage both mentally and physically for a term that extends beyond the time 
frame of the insult. 
1.3 Benefits and Risks to Iron Supplementation 
Vitamin D is the only nutrient currently recommended for supplementation in infants within 
the first year of life (Canadian Pediatric Society, 1998). While any wide spread supplementation 
recommendation has to be debated and the benefits must far outweigh the risks for the target 
population there does appear to be a case for iron supplementation of exclusively breastfed 
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infants. The potential risks of iron supplementation are oxidative damage to the gastrointestinal 
tract, unfavourable microbial colonization of the gut, diarrhoea or constipation, impaired mineral 
absorption and hereditary hemochromatosis. While these potential risks of supplementation are 
serious there are also benefits to iron supplementation. The problem of iron deficiency in infants 
has been described as a "tragedy", given that it is easily identifiable and treatable yet it goes 
undetected in many infants unUI it reaches the late stages demonstrating anaemia (Buchanan, 
1999). If a portion greater then 5% of a population suffers from a health related problem it rates as 
a public health concern (WHO, 2001). Since 10 .... 28% of exclusively breast fed infants suffer from 
IDA the problem should rate as a moderate public health concern (WHO, 2001). Yet it is not truly 
recognized as a major concern for parents who choose to exclusively breast-feed. 
It is known that the iron content of human breast milk is low compared to the infants 
metabolic need and decreases over the course of lactation (Siimes et al, 1979; Fransson et al, 
1984; Fomon, 1993; Lonnerdal and Hernell, 1994). Given the metabolic need for iron of infants 
through the first year of life and the inability to increase breast milk iron concentrations through 
maternal dietary intervention the argument for supplementation becomes stronger (Lonnerdal, 
1986; Arnaud et al, 1993; Fomon, 1993; Zavaleta et al, 1995). 
There is hesitation in recommending iron supplementation for infants because infants not 
requiring additional iron may develop complications. There is a proportion of the population who 
suffer from hemochromatosis, a metabolic disorder caused by a mutation in the HFE gene that 
controls iron uptake in the gastrointestinal tract and can lead to dangerous levels of circulating and 
stored iron (Beutler et al, 2001 ). This disorder is a rare metabolic disorder but does effect 3% of 
the population as the homozygous form and 2-24% as the heterozygous form (Beutler et al, 
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2001). Infants with this disorder would be at a higher risk of oxidative damage (liver damage, 
diabetes mellitus, cardiomyopathy and arthritis) from the increased circulating iron caused by even 
the mild iron supplementation chosen for the present study (7.5 mg FeS04/day). 
Potential changes to the micorflora of the infant gut have been described as a potential 
problem with iron supplementation. The intestinal microflora of the infant gut will vary according to 
geographic location and socio-economic status but may also be altered by dietary factors 
(lundquist et al, 1985). Favourable colonization may not occur due to treatment with antibiotics 
and the presence of high iron in the diet may lead to unfavourable bacterial colonization and 
diarrhoea (Hallet al, 1989). While there is a difference in the microflora of breastfed infants 
compared to those that are fed a high iron formula there does not appear to be enough evidence to 
suggest that the presence of iron or the difference in gastrointestinal microflora is associated with 
any increase in diarrhoea (Scariati et al, 1997; Orrhage and Nord, 1999). 
One risk associated with iron supplementation that has not been clearly elucidated is 
impairment in the absorption of other minerals. Iron supplementation at a high level has been 
shown to inhibit zinc absorption in adults nearly 50% (O'Brien et al, 2000). The addition of zinc to 
the supplementation regime does not counteract the negative effect of iron on zinc absorption 
(O'Brien et al, 2000). The choice of weaning foods may exacerbate this effect as was shown in a 
cohort of Swedish infants (Persson et al, 1998). The effects of low iron supplementation on zinc 
absorption have not been evaluated to the knowledge of the author. Other minerals could 
potentially be affected by iron supplementation given similar transport pathways in the intestine but 
these have not been investigated. 
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A further potential risk of iron supplementation in infants is the possibility of oxidative 
damage to tissue. Free radical mediated tissue injury is becoming an increasingly widespread 
concern {Halliwell, 1994). Administering supplemental iron poses some level of risk if the infant's 
antioxidant capabilities are unable to cope with the added stress. It has been clearly demonstrated 
that individuals consuming diets high in lipids will produce correspondingly increased levels of free 
radicals {Erhardt, 1997). Infants who are exclusively breastfed receive the majority of their calories 
from lipids, as high as 60% putting them at risk for having habitually higher levels of free radicals in 
the gastrointestinal tract (Fomon, 1993). Animal studies have shown prolonged exposure to high 
levels of iron will increase lipid peroxidation in the intestinal mucosa and possibly affect cell 
proliferation (Lund, 1998; Lund, 2001 ). In adult human studies, it has been shown that 
supplementary iron at a level of 19 mg per day was enough to cause increased free radical 
production in the feces of the volunteers (Lund, 1999). There was no indication that the increase in 
free radical production in the feces had any deleterious effects on the volunteers. No 
gastrointestinal problems were reported with a low level of iron supplementation in infants in a pilot 
study at the University of Iowa investigating the iron status with iron supplementation at 7.0 mg iron 
per day (Ziegler, abstract). 
1.4 Focus of Study 
Samuel Fomon has been one of the first to recommend iron supplementation to 
exclusively breastfed infants (Fomon, 2001 ). IDA challenges between 10- 28% of breastfed 
infants but the condition is both avoidable and preventable. It is reasonable to assume that mild 
iron supplementation between 1 and 6-months of age for healthy, term, exclusively breastfed 
infants will improve iron status in the first year of life. Mild iron supplementation should not 
20 
aggravate normal physiological iron metabolism nor should It pose any gastrointestinal challenge to 
the infants. 
The study presented in this manuscript focused on the haematological benefits of 7.5 mg 
per day of iron supplementation over the first 6 months of life. This study also assessed the dietary 
intake of infants during this period - including the iron concentration of human mflk along with the 
antioxidant responses to iron supplementation and a pilot study focusing on the free radical 
generating potential of infant feces during supplementation. The present study used an intent to 
treat protocol, where all infants enrolled were included in data analysis irrespective of supplement 
compliance provided that samples were collected at all clinics. This protocol was chosen to ensure 
results reflected the general population, accounting for the fulf range of prescription compliance. 
The study attempts prevent depletion of iron store in infants between 1 - 6 months of age. 
The design is unique in this respect as most previous studies of ID and IDA in infants through the 
first year of life focus on treatment after depletion of stores has occurred. Therefore, the first 
hypothesis of this study is, mild iron supplementation of exclusively breastfed infants between 1 - 6 
months at a level of 7.5 mg iron per day will have an appreciable effect by 6 months on iron status 
as measured by haemoglobin, hematocrit, MCV and plasma ferritin compared with a control 
placebo group. The objective of the first hypothesis is to compare the haematological data of the 
study and placebo groups, identifying any benefits or negative aspects to iron supplementation in 
this population. Critics of recommending supplements to breastfed infants, even those at risk of 
developing IDA may suggest that there are potential hazards to providing elemental iron to this 
population. Iron is a powerful oxidizing agent and has to potential to cause oxidative damage to 
organisms in high concentrations. To address this concern the level of iron supplementation was 
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set at half the amount an infant of the same age but fed commercial formulas receive. This level 
should prove to be safe. The second hypothesis of the study is there will be no negative oxidative 
responses will result from this level of iron supplementation. To prove this hypothesis the study will 
assess the antioxidant status of the infants at 1 month for a baseline and again a 3.5 and 6 months 
using infant plasma FRAP and erythrocyte catalase and SOD as indicators and a pilot study will be 
conducted to examine the free radical generating capacity of the infants' feces related to iron 
concentration in feces. 
Central to the study is the argument of whether or not human breast milk provides 
adequate amount of iron for the infant during the first 6 months of life. There has been a wide 
range of breast milk iron concentrations published over the last 4 decades. If the calculations of 
iron requirement of Fomon (1993) are valid some of these published ranges of iron concentration 
appear to leave the infant short of the required intakes until solid, iron rich foods are introduced to 
the diet. The last hypothesis of the study is the iron concentration of human breast milk is actually 
at the lower end of the published range and method sensitivity will play a part in the reported value. 
To investigate this possibifity we determined the concentration of iron in human breast milk from a 
sub-set of mothers enrolled in the study, comparing common methods for the determination of iron 
in biological fluids. 
This study will contribute to the area of infant iron nutrition by providing answers to some 
key questions currently in the literature on this subject. If mild supplementation in deed does 
prevent the depletion of iron stores of infants', ages 1 -6 months, then we need to develop a tool 
to distinguish those infants who will develop IDA from those who will not. It is not a goal of this 
study to recommend wide spread iron supplementation of all breastfed infants but rather to 
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determine if IDA can be prevented during the critical periods of infant growth that occurs in the first 
6 months of life. If no adverse gastrointestinal side effects or change in antioxidant status it should 
be accepted that treatment at this concentration of iron is safe. While an infant may not need 7.5 
mg/day to prevent IDA or depletion of iron stores, the study should provide a clear starting point to 
determining the amount required. The results from the breast milk analysis will answer the 
question of whether or not infants (from birth to 6 months) are meeting their metabolic requirement 
for iron. Together with the data on the effectiveness of iron supplementation and its safety the 
breast milk iron analysis will help to confirm if there is a proportion of the breastfed population that 
requires iron supplementation from birth until the appropriate iron rich solid foods are introduced. 
This study examines IDA from a unique perspective; preventative opposed to reactive, as has been 
investigated in past studies on the subject. The data and analysis from this study will make a 
significant contribution to the area of infant iron nutrition. 
23 
Chapter 2: Methods and Materials 
2.1 Study Summary 
This analysis was designated to be an intermediate biochemical analysis of a larger study 
investigating the haematological and cognitive benefits of supplementing exclusively breast-fed 
infants from 1 month to 6 months of life. Figure 2.1 illustrates the overall study design and 
summarizes the key factors of the original study design. Figure 2.2 illustrates the aspects of this 
intermediate biochemical analysis. 
2.2 Subject Selection 
Subjects were recruited by our research nurse in the days following birth once suitable 
candidates were identified by the medical staff at the Grace General Obstetrics Unit and 
Obstetrics/Gynaecology Unit of the Health Sciences Centre. All subjects were healthy, term, 
Caucasian and exclusively breast-fed infants. Exclusive breast feeding for the purpqses of this 
analysis and the larger study is defined as > 90% of all nutrients an infant receives from breast 
feeding. Parents were asked to attempt exclusive breast feeding until after the 3.5 month clinic 
and if possible until after the 6-month clinic. All parents were asked to comply with the 
recommendations of the Canadian Paediatric Society (1998) for nutrition in healthy term infants. 
All parents were informed verbally and in writing as to the study protocol. 
For the original study, design there was a requirement for 220 total infants, which would 
allow for 100 infants per group assuming 10% attrition. This number of infants would be required 
to demonstrate a 10% difference between the groups using the BSID psychological tests. When 
the intermediate analysis was undertaken, 20 infants per study group (supplemented and placebo) 
had been seen at the 6-month clinic. Not all infants were able to provide enough blood sample for 
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all analysis. It was decided that due to funding and timing restraints the analysis would be carried 
out at this point with this number of subjects despite the fact there may not be enough subjects to 
detect differences with clinically significant power. The number of subjects used for each test or 
assay is presented in the results section along with the corresponding observed power using this 
sample. 
2.3 Dietary Records 
Dietary records were supplied to the parents several days before each clinic with 
instructions to record all food intake and amounts for study subjects. These records were collected 
by clinic staff and entered into a nutrient database. Average amounts of breast milk consumed at 1 
and 3.5 month was assumed to be 750 ml/day and 650 ml/day at 6 months (Heinig, 1993, Dewey, 
2001). 
2.4 Fecal Samples 
Fecal samples from infants were collected by parents (using acid washed plastic 
disposable spoons and acid washed plastic bags provided by the investigators) and brought to 
healthy baby clinics. Samples were frozen at -20 degrees Celsius until analysis. Some parents 
produced frozen samples while others brought fresh feces to clinics. The investigators have 
considered this and realize that fecal analysis is limited to aspects which would be unaffected by 
this handling. Analysis was limited to fecal iron content and MSA production. Both were a function 
of iron content and our interpretation is limited to this respect. 
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Figure 2.1 Complete study summary flow chart. 
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Figure 2.2 Intermediate biochemical analysis flow chart. 
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2.5 Blood Sampling and Processing 
2.5.1 Blood Sampling 
Blood was drawn by technician using one of two methods. A butterfly catheter and 3 ml 
syringe was used to draw blood from the back of the hand in infants 1 month of age and 
transferred to a Becton Dickenson sodium heparin sprayed vacutainers tube. Infants 3.5 months of 
age and older had blood draw by brachial venipuncture using the previously described vacutainers. 
After CBC and haemoglobin determination samples were aliquoted to acid washed 1.8 ml 
Eppendorf tubes and were then centrifuged at 5000 rpm for 10 minutes to separate the sample into 
fractions. The plasma layer was removed and aliquoted into 100 f..l.l capped tubes. The remaining 
red cell layer was washed 3 times by adding approximately an equal amount of isotonic saline, 
inverted and centrifuged at 5000 rpm. Washed, packed red blood cells were aliquoted into acid 
washed 100 f..l.l capped tubes or 1.8 ml Eppendorf tubes for later analysis. All blood samples were 
stored under nitrogen at -70 degrees Celsius until analyzed. 
2.5.2 Haemoglobin, Hematocrit and Mean Corpuscular Volume Determination 
Forty-four f..I.L of whole blood was used for the determination Hgb, Hct and MCV by 
automated Coulter Counter Model Sx. Hgb was determined by lysing the cells in a portion of the 
aliquot to release the haemoglobin into a dilute Drabkin's reagent (1 :500) and measuring 
spectrophotometrically the absorbance at 540 nm. The Coulter principle is the basis for cell 
counting and sizing in the Coulter Counter. Measurable changes in resistance correspond to cell 
size and numbers when nonconductive particles (cells) are passed through a precisely controlled 
aperture in an electrolytic solution. The method is the standard in cell counting and sizing 
protocols. Hct (packed cell volume; pcv) was determined by calculations based on the total cell 
count of the sample. MCV is automatically determined by the following equation: 
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PCV 
MCV= --X 10 
RBC 
2.5.3 Plasma Ferritin Determination 
Plasma ferritin was determined using the IMx System microparticle enzyme immunoassay 
(Abbott Diagnostics, Chicago, IL; #2219-20). Solid phase rabbit polyclonal antibodies for human 
ferritin and soluble phase mouse monoclonal antibodies for human ferritin were used in this 
sandwich assay. The resulting florescence was measured on a micro plate reader according to the 
standards contained in kit. 
2.5.4 Criteria for Iron Status 
Iron status was measured using the criteria outlined in Table 2.1. These criteria were 
determined by examining those used by other researchers and the reported normal values for 
infants at these ages (Domell6f et al, 2001 ; Moe, 1965; Persson et al , 2001 ; Pizarro et al, 1991; 
Arvas et al, 2000; WHO, 2001). In summary, an infant was regarded as iron sufficient if the 
haemoglobin was greater than 110 g/L and plasma ferritin was greater than 12 ~g/L. Iron 
deficiency without anaemia had two classifications: 1) all haematological parameters normal with 
plasma ferritin less than of equal to 12 ~g/L ; 2) plasma ferritin greater than 12 ~g/L but 
haemoglobin less than or equal to 110 g/L with one of either hematocrit or MCV below the cut-off 
value for that parameter. Iron deficiency anaemia was classified by two sets of criteria also: 1) 
haemoglobin and plasma ferritin less then the specified cut-off values; 2) normal plasma ferritin but 
haemoglobin, hematocrit and MCV below the cut-off values. Incidences of each ID and IDA was 
recorded at each clinic time. 
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2.6 Breast Milk Collection and Analysis 
2.6.1 Breast Milk Collection and Storage 
Mothers in the study were asked to provide a sample of milk for mineral analysis if possible 
at each clinic. Each mother expressed the milk manually and collected it in 1 0 ml acid washed 
polypropylene capped test tubes. The test tubes were transported on ice to the laboratory where 
they were aliquoted to 1.5 ml acid washed Eppendorf tubes and stored at -20 degrees Celsius until 
analyzed. 
2.6.2 Breast Milk Iron by Diluted Direct Graphite Furnace Atomic Absorption 
Spectophotometry 
The direct analysis was carried out in a Perkin-Elmer 2380 Atomic Absorption 
Spectrophotometer with a Perkin-Elmer Graphite Furnace and Perkin-Elmer HGA-300 Programmer 
according to Liang and associates (1989) with modifications for breast milk. Frozen samples were 
prepared by placing in a 37 degrees Celsius water bath and allowed to come to temperature. The 
samples were then taken from the water bath and diluted 20X using 1% HN03 to eliminate the 
matrix effects and obtain an iron concentration that fell along the range of standards used (0.1 0-
0.60 1-Lg/ml). Ten micro litres of sample was then injected into the GFAAS in triplicate and was 
preceded and followed by blanks of 1% HN03. Certified material, AQCS A-11 trace elements in 
milk powder (IAEA, Austria), was prepared at a theoretical concentration of 0.4 7 1-Lg Fe/ml with ultra 
pure water and treated in the same fashion as the breast milk samples to ensure accuracy. The A-
11 iron concentration was determined to be 0.40 1-Lg Fe/ml. 
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Table 2.1 Study Criteria for Iron Status 
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Table 2.1 
Haematological Iron Sufficient Iron Deficient Iron Deficiency Anaemia Index 
Haemoglobin 
> 110 g/L > 110 g/L $; 110 g/L $; 110 g/L $; 110 g/L Count plus either one plus 
Hematocrit 
> 0.330 > 0.330 < 0.330 > 0.330 < 0.330 or or 
and or 
MCV 
> 75 fl > 75 fl < 75 fL > 75 fl < 75 fL 
when when 
Serum Ferritin > 12 _gg/L $; 12 ~g/L > 12 ~g/L ~ 12 ~g/L > 12 ~g/L 
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2.6.3 Breast Milk Iron by Metbod of Addition Graphite Furnace Atomic Absorption 
speccropnotointtry 
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2.6.4 Breast Milk Iron by Flame Atomjc Absorption Spectophotcmetry 
The spectrophotometer was set to calculate the concentration based on the mean concentration of 
a triplicate set of samples. The standard of 5 ppm Fe was made in the same manner already 
stated. The samples were prepared for the flame analysis in a 5-day digestion at 70 degrees 
Celsius in concentrated ultra pure nitric acid. Five hundred micro litres of human breast milk was 
place in a Teflon tube with 1000 ~-tl of ultra pure HN03. The samples were placed on a hotplate 
and "cooked" for 5 days at 70 degrees Celsius. When the digestion was complete, heating the 
Teflon tubes to 150 degrees Celsius rapidly evaporated off the acid. One thousand microlitres of 
ultra pure H20 was added to wash the samples. The samples were heated until they were dry. 
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Th&dood samples. wel!'& brought up to a mal volume of 1000 j.a.l wt.th 0.2 N of,tra pu~ HNOl 
(Aikanani et m, '1994). The sa1'1!1{)1es were aspirated into the FAAS and coooenwtions 'llefe 
ca~r::ulater:t Cmt~ed ma~sfial, AQCS A~ 11 tmoo ~ts in niilk ~ (IAEA.~ AUi:Sitfiah was 
prrapar~ at a tihe·oretical cor£&niaoon of 0.4'7 ~ Felml with ut.tra p1.m;· water and tra·at~ i!n lhe 
serne fashion. as tile b~east mllk sarnples ro ensure ac~racy" The A~ 11 i:ron concentrat~n wa$ 
detmmin1ild to be 0.44 J.tQ! Fwrn~" 
2.7· Assays for Oxidative status 
2.7.1 Ferric ReducingAbilty of Plume Atuy (fRAP Altay} 
Aim: To assess the abilUy of biologk:al samples m reduce feme rron ta the ferroos state 
using this assay as a m-e·asure of Ina total antioxirlanl .ahity of the samp~e. 
Principle: Lo:w pH and the pr~ce of any redootant ·with a redox; potential fa'~1::1urab'~e tor 
the re.duc!tioo of Fe~ll.lfPTZ to Ftf.Hr.JPTZ (easf!y roouood o:ddmt~ wm produc.~ an it:1tense b~tJre 
oo«>ur d"'angt:L The Fellf-TP !l colour comple·x: can be rooasured by spectropootometer at a 
ma:<.l~ wavelength of 593 nm. Tba l~ absorbance over 6 minutes al: «Xltrrr ·~emperature can be 
OGi!np;aroo ~:standards of Jerroos !roo .or pllfe antlo.xidants. 
Method: 0.3 M acetic acid buffer (pH 3.6) C2H3Na02•3 H20) was mixed with 10 mM 2, 4, 
6-tripyridyl-s-triazine (TPTZ) in 40 mM HCI and 20 mM ferric chloride (FeCI2•6 H20) in a 10:1:1 
ratio respectively (reaction solution). Fifty microlitres of infant plasma were added to 1.5 ml of 
reaction solution and allowed to react for 6 minutes at room temperature. Absorbance of the 
resulting blue solution was measured spectrophotometrically at a wavelength of 593nm for 
maximal absorption. Once an average absorbance was attained, the FRAP value could be 
calculated using the following formula and the results from a standard curve of ascorbic acid 
between 100 ~M - 1000 ~M (Benzie and Strain, 1996). The FRAP value of the standard is 
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determined by its stoichiometric relationship to TPTZ. For example any species of standard that 
can donate one electron will have a FRAP value equal to its molar concentration ( 1 00 J..tM FeiiS04 
= 100 J..tM FRAP value). If the standard can donate more than one electron the FRAP value will be 
increased by that stoichiometric factor (100 J..tM ascorbic acid= 200 J..tM FRAP) (Benzie and Strain, 
1996). 
Calcul.ati.ons: 
Equation 
6 minute .1 As93nm Sample 
6 minute tl As93nm Standard 
X FRAP value of Standard = FRAP value of Sample 
(J..tM) (J..tM) 
2.7.2 Superoxide Dismutase Activity Assay 
Aim: To determine the superoxide dismutase activity from red blood cells of infants 
receiving either supplemental iron or a placebo at 1, 3.5 and 6 months of age. 
Principle: SOD activity is measured by the ability of the enzyme to prevent the oxidation 
of an indicator substance (cytochrome c) by catalyzing the following reaction: 
Reaction 2.1 
In the case of this assay the SOD will inhibit the 02·- reduction of cytochrome c by removing it from 
the medium (reaction 2.2): 
-----.• Cyt(Fe11) + 02 Reaction 2.2 
The assay is carried out at pH 1 0 to increase the sensitivity and remove the interference usually 
seen at pH 7.8. 
Method: The method is a variation of those summarized by Fridovich (1985) for the 
quantification of SOD by the xanthine/xanthine oxidase/cytochrome c methods. This procedure is 
carried out at pH 10.0 as opposed to physiologic pH to increase the sensitivity of the assay. 
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Enzyme was extracted by adding 1 00 J.!l packed read blood cells to 1 ml of cold distilled H20 and 
400 J.!l of cold extraction solution (3:1 ethanol- chloroform v/v). Suspension was vortexed for 20-
30 seconds and centrifuged at 14000 rpm for 5 -1 0 minutes. Supernant was removed and diluted 
1 :30 v/v with distilled H20 and kept in ice or frozen at- 20 degrees Celsius until analysis. Xanthine 
oxidase working reagent was prepared by mixing 80 J.tl of xanthine oxidase (Sigma Chemicals) to 
2.0 ml of sodium carbonate buffer and kept in ice until analysis was carried out. Cytochrome c 
working reagent is prepared by adding 2.0 ml of ferricytochrome c solution (0.06192g 
ferricytochrome c in 10ml sodium carbonate buffer) to 5 ml of xanthine solution (0.01521g xanthine 
in 100 ml sodium carbonate buffer) and kept at 30 degrees Celsius during assay. SOD activity is 
measured spectrophotometrically at 405 nm by adding 100 J.!l of sample to 2.0 ml of cytochrome c 
working reagent in a cuvette and mixed with 60 J.tl of xanthine oxidase, followed on a chart 
recorder. All samples were assayed in triplicate. Hgb concentrations of samples determined as 
per section 2.4.2. 
Calculations: SOD activity is determined from standard curve of 0.25-10 units SOD/ml 
of bovine serum (Sigma Chemical) and expressed as units SOD per mg Hgb. One unit of SOD will 
inhibit the rate of reduction of cytochrome c by 50% in xanthine/xanthine oxidase system under 
these reaction conditions and volumes. 
2.7.3 Assay of Catalase Activity 
Aim: To determine the specific activity of red blood cell catalase from infants receiving 
either iron supplements or placebo at age 1, 3.5 and 6 months of age based on an adaptation of 
the method outlined by Beers and Sizer (1952). 
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Principle: The specific activity is expressed as J.tmol H202 consumed/min/mg of total 
protein at 25 degrees Celsius. RBC catalase is measured by spectrophotometer and the reaction 
followed by chart recorder as it decomposes excess H202. 
Method: Ten microlitres of packed red cells were diluted with 20 mf of phosphate buffer (5 
mmol; pH 7.0) in 50 ml falcon tubes. The spectrophotometer was set to measure absorbance at 
wavelength 240 nm. Absorbance was measured in quartz cuvettes against a reference cuvette 
containing 1 ml phosphate buffer and 2 ml of sample. One millilitre of H202 was added to the 
cuvette containing 2 ml sample, quickly mixed by stirrer and placed in the spectrophotometer. 
Absorbance was measured on a chart recorder (1 volt; chart speed= 1 mm/second over the 
course of 1 minute). All samples were measured in triplicate when possible. 
Calculation: Specific activity of catalase at 25 degrees Celsius is defined as J.lmol of 
H202 consumed per minute per mg of protein in sample. The following calculation is used to 
determine the specific activity of catalase once protein concentration is estimated. 
SA (units/mg protein)= M240nmmin-
1 X 1 000 
43.6 X (mg protein X 2/3) 
ml reaction solution 
2.7.4 Protein Estimation by Lowry Assay Method 
Aim: To determine the concentration (mg/ml) of protein in packed red cell working sample 
of the specific activity of catalase assay using Folin-Ciocalteu reagent according to Lowry et al 
(1951 ). 
Method: Two solutions were prepared as the working reagents for this assay. Solution 1 
contained 6% sodium carbonate (w/v), 4% sodium tartrate (w/v) and 2% copper sulphate (w/v) 
mixed 48:1:1 respectively. The Folin-Ciocalteu reagent was diluted 2:1 (v/v) with distilled H20 . 
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Bovine serum albumin (Sigma Chemicals) of concentration 1 -100 f.l9 was used as standard for 
this assay. Reference blanks are prepared by adding 900 f.ll of distilled H20 to 100 f.ll of 1 M 
NaOH to borosilicate glass tubes. Samples were prepared by adding 600 ~-tl distilled H20, 300 f.l.l 
of diluted packed red cells and 100 1-t.i of 1 M NaOH borosilicate glass tubes. Spectrophotometer 
was set to measure absorbance at 750 nm. The remainder of the procedure was carried out under 
timed conditions for accuracy of estimation. At exactly 10-second intervals, 1 ml of Solution 1 was 
added to each test tube and allowed to stand for exactly 10 minutes at room temperature. At the 
end of ten minutes, 100 ~-tl of Solution 2 was added at 1 0-second intervals. Samples were left to 
stand for 30 minutes at room temperature and read spectrophotometrically at 750nm. All tubes 
were read within 10 minutes. 
Calculations: Protein was determined from standard curve. 
2.7.5 Methanesulfinic Acid Assay 
Aim: To compare free radical production in stool samples of infants receiving either 
supplemental iron or a placebo. 
Principle: Methanesulfinic acid is the end-product used in this colorimetric assay as an 
indication of hydroxyl radical production. The assay was used to identify differences between 
treatment groups, not to quantify absolute levels of hydroxyl radical production. 
Method: Due to the variable moisture content of infant stool (solid stool to diarrhoea), 
samples were thawed, dried at 30 degrees Celsius and 87% moisture was added to achieve 
consistent level of moisture. The assay was carried out by our modifications of the methods of 
Lund et al (1999) and Babbs and Gale (1987). Samples were weighed and homogenized, added 
to 50 ml falcon tubes and mixed with an equal amount (w/w) of distilled H20, then frozen until batch 
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analysis. One to two grams of the fecal samples (if available) were incubated overnight (18+ 
hours) in Tris buffered saline (pH 7.0) containing 5% dimethyl sulfoxide (0.7 moi/L), glucose (0.1% 
w/v) and Na2EDT A (50 mmoi/L) at 37 degrees Celsius. After incubation, samples were centrifuged 
at 900 X g for 10 minutes and supernant removed. Proteins were removed from supernate by 
lowering the pH to 1.0 using an appropriate amount of 12M HCI, allowed to stand for 10 minutes 
and centrifuged at 900 X g after which the pH of the supernatant was returned to 7.0 using an 
appropriate amount of NaOH. Supernant was stored at -20 degrees Celsius until batch analysis 
was completed. Standards of methanesulfinic acid were prepared (10- 75 mM) using incubation 
solution as solvent and treated in the same fashion as samples from this point forward. Two-
millilitre aliquots of sample were mixed well with H2S04 (200f.tl; 1 M) followed by 4 ml of 1-butanol. 
Sample was vortexed and the upper phase was transferred to another borosilicate tube and mixed 
well with 2 ml sodium acetate buffer (0.5M; pH 5.0). Sample was centrifuged at 500 X g for 3 
minutes and 1.8 ml of lower phase was transferred to a new borosilicate tube. Two hundred 
microlitres of Her was added to lower pH (pH 2.5) and 200 J.d of Fast blue BB Salt (0.03 mM) was 
added, mixed and left in the dark for 10 minutes to allow for colour development. Aliquots of 
toluene/1-butanol (1 .5-ml; 3:1) was added to each tube and mixed for 120 seconds. Samples were 
centrifuged (600 x g; 3 min) upper phase was removed and washed with 1-butanol saturated H20. 
One millilitre of pyridine was added to the samples to stabilize the colour until they could be read 
on the spectrophotometer. Samples were then read on a Spectrum 3000 spectrophotometer at 
wavelength 420 nm for maximal absorption. 
Calculation: Linear equation produced from standards was used to determine the amount 
of methanesulfinic acid produced in fecal samples. Results are expressed as mmollg wet weight 
feces. 
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2.8 Iron Content of Infant Fecal Samples 
2.8.1 Fecal Iron by Flame Atomic Absorption Spectrophotometry 
Aim: To determine the amount of iron present in fecal samples of subjects receiving iron 
supplements or placebo. 
Principle: Fecal samples were ashed and total iron present in feces was determined by 
flame atomic absorption spectrophotometry. Results are an indication of total iron loss due to fecal 
excretion including iron from dietary sources and occult iron losses. 
Method: Approximately 0.3 g of stool was transferred to a pre-weighed 10 ml beaker and 
wet weight of sample was recorded. Samples were dried at 65 degrees Celsius until a consistent 
weight was achieved. Beakers containing dried sample were transferred to a muffle furnace and 
dry ashed at 450 degrees Celsius for 48 hours. After ashing was complete, samples were allowed 
to cool to room temperature for 1 hour. Samples appeared as a white-grey powder. Concentrated 
HN03 (5-7 drops from a pasture pipette) was added to the ashed samples and left to stand for 30 
minutes. HNOJ {5 ml; 1 M) was added to the beakers containing the samples and shaken lightly 
the ash dissolved. Contents were decanted into a 10 ml volumetric flask and the beaker was 
rinsed with small amounts of 1 M HN03 bringing the volume up to the 10 ml mark. Two hundred 
microlitres of the solution were pipetted to acid washed Eppendorf tubes and brought up to 1 ml 
with ultra-pure water. Samples were run on the FAAS and compared with a standard curve 
previously prepared (1 -4 ppm or 1.0-4.0 11g/ml). The Perkin-Elmer FAAS (flame atomic 
absorption spectrophotometer) was optimized and set to measure concentration of iron using 
wavelength 'A= 248.3 nm and internally set references. The spectrophotometer was set to 
calculate the concentration based on the mean concentration of a triplicate set of samples. The 
samples were then aspirated into the FAAS and concentrations were calculated. NBS Trace 
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Elements In Water was used as a certified value for accuracy and was within 10% of reported 
value for iron. 
Calculation: Results are expressed in mg of iron per gram of dry feces. The following 
calculations are U$ed to convert the concentrations determined by FAAS to these units. 
• FAAS Cone x 5 = CONC (removes dilution factor) 
• CONC x 10 =Fe MASS (amount of iron in specific amount of ash) 
• [1/dry weigh of feces] x Fe MASS = Amount of Fe per gram of dry gram of infant feces 
2.9 Plasma Copper and Zinc by Flame Atomic Absorption 
Spectrophotometer 
2.9.1 Plasma Copper and Plasma Zinc by discrete Nebulization with FAAS 
Aim: To determine the plasma copper and zinc concentrations of infants receiving either 
iron supplements or a placebo at 1, 3.5 and 6 months of age. 
Principle: The use of discrete nebulization FAAS is preferred for an accurate 
determination of the plasma copper and zinc concentrations in infant plasma samples given the low 
blood volume obtained from infants in human investigation studies. Significantly, lower volumes of 
plasma are required for this determination as compared to conventional procedures for the 
determination of copper and zinc in biological samples. 
Method: The method used for copper determination was first described by Makino and 
T akahara ( 1991). The Perkin-Elmer 2380 Atomic Absorption Spectrophotometer was set to the 
following specifications: copper hollow cathode lamp; zinc hollow cathode lamp; slit width 0.7mm; 
wavelength set to 324.8 nm (Cu) or 213.9 (Zn) for maximal absorption. All samples were analyzed 
in triplicate when possible. One hundred microlitres of 0.1 N HCI was added to 1.8 ml Eppendorf 
tubes followed by the addition of 10~d (Cu) or 20~1 (Zn) of plasma. Tubes were vortexed for 3- 5 
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seconds. Spectrophotometer was calibrated to determine concentrations between 0.2 ).!g/ml to 4.0 
~tg/ml for copper analysis and 0.2 ).!g/ml to 2.0 ).!g/ml for zinc. Appropriate reference check and 
certified standards were used to ensure accuracy. Samples were then aspirated slowly through a 
70mm Teflon capillary tube. Concentrations were determined directly from the linear equation of 
the calibration standards. 
2.1 0 Statistical Analysis 
Continuous variables were analyzed by repeated measures ANOVA, using Bonferroni p-
value adjustment and Levene's test of homogeneity of variance applied. Non parametric data 
regarding the incidence of ID and IDA was analyzed by Chi Square. Differences within groups at 
different time points was determined by Bonferroni step wise comparisons when data was 
analyzed by treatment group. Pearson correlations and linear regression was used to determine 
relationships between several possible predictors of haematological predictors of iron stores. 
Paired t-test was used for analysis of the breast milk iron concentrations by method and 
independent t test was used to compare groups at 1 - 3.5 months. The level of significance 
chosen throughout the analysis wasp< 0.05. Statistical power varied between variables 
measured however for haematological parameters a sample size of 20 is adequate to detect a 1 0% 
difference between groups with a predictive power of 80%. 
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Chapter 3: Results 
3.1 Subject Anthropometric Data 
No abnormalities were detected in the growth of the infant subjects in this study. All 
infants were compared to the normal healthy growth charts for infants. Head circumference, 
weight and length were normal for all infants irrespective of treatment group. Table 3.1 
summarizes the weight, body length and head circumference of the infants separated by treatment 
group and age. 
3.2 Dietary Intake Data and Problems with Study Medication 
There were no irregularities found in the three-day dietary records obtained from the 
subjects' mothers between the two treatment groups. Total energy, protein, carbohydrate and fat 
were assessed in ensure consistency between infant diets. Dietary iron was assessed to ensure 
consistency in dietary intakes of iron (supplement not included). Dietary copper and zinc were 
assessed to compare to plasma levels and ensure consistency between groups. Dietary ascorbic 
acid was measured to ensure intake in each group was consistent, as ascorbic acid will increase 
absorption of dietary iron. Dietary ascorbic acid along with selenium were assessed and compared 
to antioxidant status. The intake of energy, protein, carbohydrate, fat, iron, copper, zinc, selenium 
and ascorbic acid were consistent between the two groups at 1, 3.5 and 6 months of age when 
analyzed by repeated measures AN OVA (Appendix A). No difference was observed between 
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Table 3.1 Anthropometrical Measurements of Two Study Groups Over Duration of Study 
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Table 3.1 
Weight (kg) Length (em) Head Circumference (em) 
Age Supplement Placebo Supplement Placebo Supplement Placebo 
Birth 3.6 (0.6) 3.7 (0.5) 51 .1 (1.8) 50.9 (1 .7) 34.9 (1.2) 34.2 (2.7) 
1 Month 4.6 (0.7) 4.8 (0.5) 53.9 (5.2) 55.3 (2.6) 37.9 (1 .1) 38.4 (1 .0) 
3.5 Month 6.5 (0.9) 6.8 (0.9) 62.9 (2.1) 63.6 (1 .9) 41 .4 (0.9) 41 .8 (1 .1) 
6 Month 7.8(1.0) 8.2 (1.0) 67.9 (2.4) 68.2 (2.3) 43.5 (1 .0) 44.2(1 .1) 
Values are reported as mean(+/- standard deviation in parenthesis) N = 20 per group. No 
difference seen between groups at any clinic time as measured by repeated measures ANOVA. 
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groups in reported problems with taking study medication when analyzed by Chi Square (Appendix 
B). 
3.3 Iron Status Determination from Haematological Data 
Based on the definitions of iron deficiency and iron deficiency anaemia described in 
Chapter 2 (table 2.1) the following haematological data were collected and used to determine the 
rates of iron deficiency and iron deficiency anaemia found in the subjects by six months. 
3.3.1 Haemoglobin, Hematocrit and MCV 
Although baseline haemoglobin concentrations for subjects did not differ, by six months of 
age a difference was seen between the supplemented group and the placebo group when tested 
by repeated measures AN OVA (2 (groups) x 3 (time periods))(F (1, 38) = 6.89; p = 0.01 ; figure 3.1 ) 
with an observed power of 0.73. The placebo group haemoglobin decreased significantly by 6 
months compared to the 1-month baseline blood sample (F (1 , 19) = 5.31 ; p = 0.03; figure 3.1). 
Baseline hematocrit (measured as percent red cells per total blood volume) between subjects also 
differed by six months when tested by repeated measures ANOVA (2 (groups) x 3 (time periods))(F 
(1, 38) = 5.86; p = 0.02; figure 3.3) with an observed power of 0.66. Mean corpuscular volume 
(MCV) of all infants dropped over the course of the study. This phenomenon is normal in infant 
development and was expected. However, a difference was seen in the MCV between the infants 
receiving supplement and those receiving placebo as early as 3.5 months (F (1 ,38) = 5.86; p=0.02; 
figure 3.3) with an observed power of 0.66. 
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Figure 3.1 Haemoglobin concentration of infants measured at 1, 3.5 and 6 months of age, 
receiving either supplemental iron (7.5 mg/day) or placebo. Placebo group declines over 6 
months while the supplemented group maintains haemoglobin levels. Mean+/- SEM (error 
bars) p=0.01 at6-months; N = 20 per group. 
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Figure 3.1 Haemoglobin concentration of infants measured at 1, 3.5 and 6 months of age, receiving either 
supplemental iron (7.5 mg/day) or placebo. Placebo group declines over 6 months while the supplemented 
group maintains haemoglobin levels. Mean +/- SEM (error bars) p=0-01 at 6-months; N = 20 per group. 
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Figure 3.2 Hematocrit of infants receiving iron supplements (7.5 mg/day) or a placebo 
measured at 1, 3.5 and 6 months of age. Mean +/- SEM (error bars) p<0.02 at 6 months; 
N = 20 per group. 
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Figure 3.2 Hematocrit of infants receiving iron supplements (7.5 mg/day) or a placebo measured at 1, 3.5 and 6 
months of age. Mean+/- SEM (error bars); N = 20 per group. 
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Figure 3.3 Mean corpuscular volume of infants receiving iron supplements (7.5 mg/day) or a 
placebo measured at 1, 3.5 and 6 months of age. Both groups decrease over time as is 
expected for MCV but the supplemented group averages larger red blood cells by 6-months 
Mean+/- SEM (error bars) p<0.02 at 6 months; N = 20 per group. 
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Figure 3.3 Mean corpuscular volume of infants receiving iron supplements (7.5 mg/day) or a placebo 
measured at 1, 3.5 and 6 months of age. Both groups decrease over time as is expected for MCV but the 
supplemented group averages larger red blood cells by 6-months Mean +1- SEM (error bars) p<0.02 at 6 
months; N = 20 per group. 
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3.3.2 Plasma Ferritin 
Plasma ferritin is often used as an indication of the iron stores available in humans. 
Plasma ferritin did not differ between the treatment and placebo group through the five-month 
protocol when analyzed by repeated measures AN OVA (F(1, 33) = 0.05; p = 0.85; figure 3.4). The 
rate of change in the plasma ferritin did show a significant difference between the baseline ferritin 
(1-month) and the 3.5-month ferritin (F(1, 32) = 1.69; p = 0.026; figure 3.5). This decline in iron 
stores was more rapid in the placebo group over the treatment group indicating the latter group had 
protection against the drop. 
3.3.3 Incidence of Iron Deficency and Iron Deficency Anemia 
Based on the data collected from the haematological analysis, all infants were assessed 
for iron deficiency and iron deficiency anaemia according to the study criteria (table 2.1). The 
percentage of infants suffering from ID and IDA at each clinic visit is presented in table 3.2. If it is 
assumed that 20% of infants will suffer from 10 and 10% will suffer from IDA these values should 
have been seen in this study group (Friel et al, 1997; Innis et al, 1997). These levels where 
chosen as the expected values for the Chi Square analysis. There were more then expected 
cases of ID (25%) at 1-month in the supplemented group (X2 = 5.00; p = 0.025) while the placebo 
group has an expected number of ID cases (20%). However, by 6 months the placebo group had 
significantly more cases 10 (55%) than expected (X2 = 45.00; p <0.0001). While IDA was seen in 
20% of the subjects in the placebo group compared to 10% in the supplemented group, this was 
not significantly higher then the expected incidence of 10% (X2 = 1.053; p = 0.305). 
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Figure 3.4 Plasma ferritin of infants receiving iron supplements (7.5 mg/day) or a placebo 
measured at 1, 3.5 and 6 months of age. Mean +/-SO (error bars); N = 16 (supplemented group) 
and N = 19 (placebo group). 
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Figure 3.4 Plasma ferritin of infants receiving iron supplements (7.5 mg/day) or a placebo measured at 1, 3.5 and 6 
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Figure 3.5 Mean change in plasma ferritin between clinic visits (1 I 3.5 and 6-months). Mean 
+I- SEM (error bars); N = 16 (supplemented group) and N = 19 (placebo group). :t: Placebo 
group plasma ferritin declined significantly faster then the supplemented group from 1 to 3.5 
months (F(1 I 32) = 1.69; p = 0.026). 
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Figure 3.5 Mean change in plasma ferritin between clinic visits (1 , 3.5 and 6-months). Mean +/- SEM (error bars); 
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Table 3.2 Incidence of Iron Deficiency and Iron Deficiency Anaemia Through 6-Months. 
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Table 3.2 
Age 
1 Month 
3.5 Month 
6 Month 
Iron Deficiency 
Su lement Placebo 
25 (5/20) 20 (4/20) 
1 0 (2/20) 15 (3/20) 
20 ( 4/20) 55t ( 11 /20) 
Iron Deficiency Anaemia 
Su lement Placebo 
0 (0/20) 0(0/20) 
0 (0/20) 0 (0/20) 
5 (1/20) 10 (2/20) 
Values in parenthesis are number of cases from total subjects. t denotes significantly different 
from expected value (X2 = 5.00; p = 0.025). 
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3.3.4 1-Month Haemoglobin as a Predictor of Infant Plasma Ferritin at 3.5 and 6-Months 
The haematological data was examined for relationships that might serve as predictors of 
infant iron stores. The infants haemoglobin at 1-month appears to be a useful predictor of the 
infant iron stores as plasma ferritin. The supplemented infants' 1-month haemoglobin showed a 
correlation with the 3.5-month plasma ferritin but not with 6-month plasma ferritin (Figure 3.6; 
Pearson correlation coefficient= 0.554; p < 0.03; two tailed). The placebo infants' 1-month 
haemoglobin correlated to both the 3.5-month and 6-month plasma ferritin (Figure 3.7; Pearson 
correlation coefficient= 0.457 at 3.5-month and Figure 3.8; Pearson correlation coefficient= 0.462 
at 6-month; p < 0.05; two tailed). The lack of correlation between the supplemented infants' 
haemoglobin and the 6-month plasma ferritin may be due to the positive effects of the iron 
supplement on iron status. 
3.4 Antioxidant Status of Subjects 
3.4.1 Ferric Reducing Antioxidant Power Assay 
The FRAP assay was chosen as the measure of total antioxidant capacity for the subjects 
in the study (Benzie and Strain, 1996). Chosen for its relative simplicity and high reproducibility, 
the FRAP assay is an indication of the total reducing ability of the infant plasma sample. This 
measure accounts for enzymatic and non-enzymatic systems present in plasma samples. There 
were no differences between the infants with respect to treatment protocol (F( 1, 31) = 0.011 ; p = 
0.918; figure 3.9). 
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Figure 3.6 Supplemented infants 3.5-month plotted against the 1-month haemoglobin. 
Pearson correlation coefficient= 0.554 at p < 0.03 (two tailed) N= 17. 
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Figure 3.6 Supplemented infants 3.5-month plotted against the 1-month haemoglobin. Pearson correlation 
coefficient = 0.554 at p < 0.03 (two tailed) N= 17. 
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Figure 3.7 Placebo infants' 3.5-month plotted against the 1-month haemoglobin. Pearson 
correlation coefficient= 0.457 at p < 0.05 (two tailed) N= 19. 
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Figure 3.7 Placebo infants' 3.5-month plotted against the 1-month haemoglobin. Pearson correlation 
coefficient= 0.457 at p < 0.05 (two tailed) N= 19. 
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160 
Figure 3.8 Placebo infants' 1-month haemoglobin plotted against plasma ferritin at 6-
months demonstrating a possible predictor of 6-month iron stores. Pearson correlation 
coefficient= 0.457 at p < 0.05 (two tailed) N= 19. 
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Figure 3.8 Placebo infants' 1-month haemoglobin plotted against plasma ferritin at 6-
months demonstrating a possible predictor of 6-month iron stores. Pearson correlation 
coefficient= 0.457 at p < 0.05 (two tailed) N= 19. 
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3.4.2 Erythrocyte Catalase Specific Activity 
The catalase specific activity was measured to determine if the supplemental iron would 
invoke an increase in the activity of catalase. No difference was seen in the catalase specific 
activity between the two treatment groups (F(1, 34) = 0.004; p = 0.949; figure 3.10). These 
findings are in agreement with the lack of difference in the FRAP values recorded for both groups 
3.4.3 Erythrocyte Superoxide Dismutase Activity 
The erythrocyte SOD activity was also measured as an indication of any antioxidant 
response to the supplemental iron. Erythrocyte SOD was also used as an indicator of impaired 
copper and/or zinc absorption due to the supplemental iron as Cu and Zn deficiencies would be 
detectable in this enzyme. No difference was seen between either the supplemented group or the 
placebo group with respect to SOD levels (F(1, 33) = 0.212; p=0.648; figure 3.11). There was no 
indication of any impaired copper/zinc absorption as measured by SOD levels given the fairly 
stable enzyme activity levels seen in the supplemented group (figure 3.11 ). 
3.5 Plasma Mineral Concentration 
3.5.1 Plasma Copper Concentration 
The plasma copper concentration was measured to insure there was no inhibition of 
dietary copper absorption in the gastrointestinal tract due to the supplemental iron. No difference 
was seen between groups in the plasma Cu concentrations at any of the clinic times (F(1, 27) = 
0.041; p = 0.842; figure 3.12). There was a significant increase in the plasma Cu concentrations of 
both groups over 1- 3.5 month period (F(1 , 15) = 56.6; p < 0.0001; figure 3.12). 
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Figure 3.9 FRAP value expressed asJ..lmoi/L ascorbic acid for of infants receiving iron 
supplements (7.5 mg/day) or a placebo measured at 1, 3.5 and 6 months of age. Mean+/-
SEM (error bars); N = 16 (supplemented group) and N = 17 (placebo group). 
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Figure 3.9 FRAP value expressed as11moi/L ascorbic acid for of infants receiving iron supplements (7.5 mg/day) or a 
placebo measured at 1, 3.5 and 6 months of age. Mean +/- SEM (error bars); N = 16 (supplemented group) and N = 17 
(placebo group). 
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Figure 3.10 Erythrocyte catalase specific activity measured as specific activity per mg of 
protein for infants receiving iron supplements (7.5 mg/day) or a placebo measured at 1, 3.5 
and 6 months of age. Mean+/- SEM (error bars); N = 18 (supplemented group) and N = 19 
(placebo group). 
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Figure 3.10 Erythrocyte catalase specific activity measured as specific activity per mg of protein for infants receiving 
iron supplements (7.5 mg/day) or a placebo measured at 1, 3.5 and 6 months of age. Mean+/- SEM (error bars); N = 18 
(supplemented group) and N = 19 (placebo group). 
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Figure 3.11 Erythrocyte superoxide dismutase expressed as units of SOD per mg of 
haemoglobin for infants receiving iron supplements (7.5 mg/day) or a placebo measured at 1, 3.5 
and 6 months of age. Mean+/- SEM (error bars); N = 17 (supplemented group) and N = 19 
(placebo group) 
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Figure 3.11 Erythrocyte superoxide dis mutase expressed as units of SOD per mg of haemoglobin for infants receiving iron 
supplements (7.5 mg/day) or a placebo measured at 1, 3.5 and 6 months of age. Mean+/- SEM (error bars); N = 17 
(supplemented group) and N = 19 (placebo group) 
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3.5.2 Plasma Zinc Concentration 
Plasma zinc concentrations were also monitored to determine if the supplemental iron 
inhibited the absorption of dietary zinc. Plasma zinc, like plasma copper was determined by atomic 
absorption spectrophotometry using discrete nebulization. No difference was measurable between 
the two groups (F(1, 27) = 0.041; p = 0.842; figure 3.13) but the supplemented group had a 
significant rise in zinc plasma concentrations between the 3.5 and the 6-month blood samples (F(1, 
16) = 18.8; p = 0.01; figure 3.13). There are several plausible reasons for this increase that are 
described in the discussion. 
3.6 Human Breast Milk Iron Concentrations 
Human breast milk iron concentration was measured in both groups to obtain the mean 
level of iron intake for the study subjects and to compare three common methods used in the 
literature to determine levels of iron in human breast milk. These concentrations were also 
compared to the maternal haemoglobin concentration measured in hospital during delivery. 
3.6.1 Breast Milk Iron Concentrations 
The breast milk iron concentrations were measured at 1 and 3.5 months by direct GFAAS and 
method of additions GFAAS and by FAAS. The change in iron concentration from 1 to 3.5 months 
was measured as well as the difference between the three methods at each sample time. A 
difference was show to exist between the use of direct GFAAS and FAAS at 1-month (paired t-test 
p = 0.03) while both GFAAS methods differed from the FAAS at 3.5-months (paired t-test p = 0.01; 
figure 1). FAAS yielded a consistently higher concentration of iron in both milk samples (1 -month 
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and 3.5-month; figure 1 ). There was no difference between the two GFAAS methods at either time 
point but the characteristic decline over lactation was seen between milk samples (figure 1). 
3.6.2 Maternal Haemoglobin as Predictor of Breast Milk Iron Concentration 
The maternal haemoglobin obtained at the time of delivery was used as an indicator of 
maternal iron status and compared to the 1-month breast milk iron concentration to determine if 
any relationship existed (figure 3.1 7; direct GFAAS). No relationship was seen and in support of 
previous reports maternal iron status is independent of maternal breast milk iron concentrations. 
3.6.3 Maternal Haemoglobin as a Predictor of Infant Haemoglobin at 1 Month 
The scatter plot of infant haemoglobin and maternal haemoglobin does not demonstrate any type 
of relationship that would yield any predictive value for infant haemoglobin. As with the 
haemoglobin and 1-month breast milk iron concentrations there is no significant relationship (figure 
3.18). 
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Figure 3.12 Plasma copper concentrations are expressed as ~-tQ/ml plasma for infants 
receiving iron supplements (7.5 mg/day) or a placebo measured at 1, 3.5 and 6 months of 
age. Mean+/- SEM (error bars); N = 16 (supplemented group) and N = 13 (placebo group) 
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Figure 3.12 Plasma copper concentrations are expressed as J.t.g/ml plasma for infants receiving iron supplements (7.5 
mg/day) or a placebo measured at 1, 3.5 and 6 months of age. Mean+/- SEM (error bars); N = 16 (supplemented group) 
and N = 13 (placebo group) 
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Figure 3.13 Plasma zinc concentrations are expressed as J.!Qiml plasma for infants receiving 
iron supplements (7.5 mg/day) or a placebo measured at 1, 3.5 and 6 months of age. Mean +/-
SEM (error bars); N = 18 (supplemented group) and N = 16 (placebo group). 
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Figure 3.13 Plasma zinc concentrations are expressed as 1-lg/ml plasma for infants receiving iron supplements (7.5 
mg/day) or a placebo measured at 1, 3.5 and 6 months of age. Mean +/- SEM (error bars); N = 18 (supplemented 
group) and N = 16 (placebo group). 
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Figure 3.14 Iron concentration of human breast milk measured at 1 and 3.5 months by 
direct GFAAS, methods of addition GFAAS (N = 22 at 1 month and N = 25 at 3.5 months 
for both direct and methods of addition) and FAAS (N = 10). Concentration is expressed 
as JlQ/ml of human breast milk. Mean+/- SO (error bars). t =Difference between 
method; p<0.05. :t: =Difference between time within same method; p<0.05. 
82 
1.20 
1.00 
'E o.so 
-t:n 
::s 
-s::: 
0 ;: 0.60 
E 
..... 
s::: 
(1,) 
C.) 
s::: 8 0.40 
0.20 
Breast Milk Iron Concentrations Measured at 1 and 3.5-Months 
1-fv'bnth 3.5-Month 
Time of Milk Collection 
[]Direct GF AAS • Metlods of Addition GF AAS Ia FAAS 
Figure 3.14 Iron concentration of human breast milk measured at 1 and 3.5 months by direct GF AAS, methods of addition 
GFAAS (N = 22 at 1 month and N = 25 at 3.5 months for both direct and methods of addition) and FAAS (N = 10). 
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Figure 3.15 Maternal breast milk iron concentrations plotted against maternal haemoglobin at 
delivery (N = 21). 
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Figure 3.15 Maternal breast milk iron concentrations plotted against maternal haemoglobin at delivery (N = 21 ). 
85 
Figure 3.16 Maternal haemoglobin plotted against infant haemoglobin at 1 mont 
(N = 39). 
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Figure 3.16 Maternal haemoglobin plotted against infant haemoglobin at 1 month (N = 39). 
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Chapter 4: Discussion 
4.1 General Comments 
To date there have been no intervention studies investigating the possibility of preventing 
iron store decline in healthy breast fed infants through iron supplementation. Our study has 
demonstrated the clear benefits associated with iron supplementation in infants by preventing ID at 
6 months of age. While a portion of newborns have adequate iron stores, allowing them to reach 6 
months of age before any overt signs of iron deficiency, 55% in the present study did not reach this 
benchmark age before suffering the insult of iron deficiency. The analysis of iron and 
haematological status as a function of iron supplementation has shown significant positive 
increases in Hgb, Hct and cell size (MCV) and lower incidences of I D. 
Potential risks associated with iron supplementation include increased oxidative stress and 
metabolic consequences associated with this stress, gastrointestinal discomfort of the infant from 
the ferrous sulphate supplement itself and potential negative interactions with the absorption of 
dietary zinc and copper. Assaying for activities of erythrocyte superoxide dismutase and catalase 
and measuring the total reducing ability of infant plasma (FRAP assay) between 1 - 6 months of 
age was used to assess antioxidant status. No differences were observed between the two groups 
for any of these indicators, indicating no increase in oxidative stress. Parental reporting of 
problems associated with taking the supplement, such as constipation, showed no difference 
between treatment groups and could have been explained by numerous other infant related 
situations causing the same symptoms. There were also no differences observed between 
88 
treatment groups with respect to copper or zinc absorption between 1 and 6-months of age 
regardless of treatment as measured by total plasma copper and zinc concentrations. However, 
significant increase plasma zinc concentrations between 3.5 months and 6 months was observed, 
which requires further investigation to assess whether zinc absorption was suppressed as a result 
of the iron supplement. If this were the case there would be implications for both supplementing 
breast fed infants and infant formula compositions. 
The data was also analyzed for relationships, which may provide a predictive tool to 
identify infants who are at risk of developing an 10 before 6 months of age. While there were no 
strong correlations relationships were observed between infant 1-month Hgb as a predictor of 3.5 
and 6-month plasma ferritin in the placebo group and 1-month Hgb predicting plasma ferritin in 3.5 
month supplemented infants. These relationships will need to be further investigated to determine 
if they are plausible techniques for identifying infants at risk of becoming 10 in the first few months 
of life. 
The data presented in this thesis has contributed to several gaps in the current 
understanding of 10 and IDA in breast fed infants less than 6 months of age. The decline of iron 
stores can be safely prevented by mild iron supplementation. Caution is needed as even mild iron 
supplementation may have effects on the absorption and status of other minerals, namely zinc. 
This study also demonstrated 1-month infant iron and haematological status is independent of 
maternal status at birth. There was also no relationship between breast milk iron concentrations 
and exclusively breastfed infant iron status. These thoughts are discussed in further detail in the 
reminder of this chapter. 
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4.2 Analysis of Findings 
4.2.1 Subject Anthropometric, Dietary and Racial Findings 
All infants were within the limits of normal growth compared to the standard infant growth 
charts for length, weight and head circumference (Table 3.1) (Farnan, 1993). All subjects were 
infants born at the Grace General or Health Sciences Centre Obstetrics Unit. Infants were all 
healthy at each clinic visit, displaying no signs of infection. The three day dietary records collected 
on the infants from the mothers did not reveal anything unexpected as all mothers exclusively 
breastfed at the time of the 1-month clinic with over 95% still exclusively breast feeding at 3.5 
months and a combination of breast milk, formula and solid foods by 6-months. There were no 
differences seen between the groups for the energy, protein, fat or carbohydrate intake (Appendix 
A). In addition, iron (not including supplement), copper, zinc, selenium and ascorbic acid intake did 
not differ between groups (Appendix A). With both groups virtually identical with respect to growth, 
diet and race any difference seen between the groups with respect to haematological data, 
oxidative responses and stress or plasma mineral concentrations should be due to the treatment 
medication. 
4.2.2 Breast Milk Iron Concentrations 
It is known that the levels of many human breast milk constituents do not vary greatly 
between populations of mothers throughout the world (Casey, 1996). The published values for iron 
vary as much as 66% depending on the method used. Trugo (1988) and associates reported 
mature human breast milk containing 0.90 f.!Q/ml iron in Brazil while both Siimes and associates 
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(1979) and Macy and Kelly (1961) report the value at 0.30 llg/ml iron in Finland and the United 
States respectively. Fransson and associates (1984) demonstrated that geographic region and 
socio-economic status has little effect on the concentration of iron in human milk, comparing 
Swedish women to privileged and underprivileged Ethiopian women. It was because of this wide 
range of values that we decided to compare several methods for determining iron concentrations in 
biological samples. Atomic absorption spectrophotometry is a widely used tool to determine 
mineral content in biological samples. We decided to examine 3 different methods for determining 
iron levels: graphite furnace atomic absorption spectrophotometry (direct measurement with use of 
prepared standards and method of standard additions) and flame atomic absorption 
spectrophotometry. Since the amount of iron these infants are consuming in their diet is of great 
importance, we analyzed a subset of 10 mothers' breast milk to determine the concentration of 
iron. 
Differences were found between the breast milk iron concentrations of those mothers who 
provided milk for analysis both at different times and by different analytical method. There was a 
drop in mean iron concentration between 30-day and 3.5-month milk samples, which is in 
agreement with Siimes et al (1979) and those summarized by Casey (1996). Our findings 
demonstrated mean iron concentration ranging from 0.47-0.29 mg/L from 30-day to mature milk 
at 3.5-months (figure 3.14) using the GFAAS methods while the FAAS method produced a 
consistent mean concentration of iron in both samples (0.76- 0.78 mg/L). The discrepancy 
between the results obtained by GFAAS and those by the FASS method illustrate the problems 
with reporting breast milk mineral concentrations by a variety of methods. FAAS and GFAAS are 
two common methods used to determine many minerals in biological fluids and have been used by 
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most when determining the iron concentrations (Siimes et al, 1979; Fransson et al, 1984; Fransson 
and Lonnerdal, 1980; Picciano et al, 1981; Arnaud et al, 1993; Zavaleta et al, 1995). The variety of 
ashing techniques and dilution protocols used by the different researchers are a possible reason 
for the wide range of results seen in the literature. A clear example of this effect is illustrated by 
Arnaud and associates (1993, 1995) who produced two different ranges for early breast milk iron 
by changing the procedure used. The use of a flame method on whole breast milk yielded men a 
iron concentration of 4.9Jlmoi/L while a GFAAS method using Triton X-100 as the diluent yielded 
between 6- 14 11moi/L iron with a mean concentration of 9.4 Jlmoi/L. The FAAS method with wet 
ashing of the sample used in our experiments, and used by other researchers for mineral 
determinations in milk products (Aikanani et al, 1994; Zavaleta et al, 1995), yielded consistently 
higher values for breast milk iron in our experiments compared to others (0.76 mg/L versus 0.40 
mg/L by Zavalata et al, 1995). 
We also examined the reliability of a high dilution direct method for the GFAAS, which also 
produced very reliable and reproducible values. The method of addition technique described in 
Chapter 2 (section 2.5.3) is reported to be the most effective method to remove organic matrix 
effects from biological samples (Perkin Elmer HGA 300 Method Manual; Lena Davidsson, personal 
communication). The values obtained by the method of addition and the direct diluted methods 
conform to the reported values of breast milk iron from Siimes et al (1979), Fransson et al (1984) 
and the mean of the various data summarized by Casey (1996). 
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4.2.3 Haematological and Iron Status 
The supplementation of infants 1 -6 months of age with 7.5 mg iron per day has clear 
benefit to the haematological status by 6-months. Haemoglobin and hematocrit levels were 
maintained by iron therapy compared to an 8% and 6% difference seen in the group receiving the 
placebo. While the MCV fell in both groups, those infants receiving iron had a higher cell volume at 
6-months dropping only 16% of the 1-month level compared to those receiving placebo whose 
mean volume fell 19%. While no significant difference was detected in the mean plasma ferritin 
levels between the study group and the group receiving the placebo the latter did decrease 
between blood samples at a significantly higher rate (49% versus 68%). 
The haematological data from this study compare closely to data on breast fed infants 
published by Saarinen (1978) when he examined iron status among breastfed, formula fed and 
cow milk fed infants in the first year of life. The same patterns observed by Saarinen are seen in 
the placebo group from 1 to 6-months. There is a striking difference between our supplemented 
group and the infants presented in Saarinen's study with respect to haemoglobin concentrations. 
The infants in Saarinen's study displayed a sharp decrease in haemoglobin concentration between 
1 and 4 months followed by an increase and plateau by 6 months. The iron-supplemented infants 
were able to avoid this decline in haemoglobin while the other measures of iron status, MCV and 
plasma ferritin, progressed similar to that of Saarinen's infants. 
The observation that breast fed infants usually do not display signs of iron deficiency until 
after 6 months (Lonnerdal and Hernell, 1994; Walter et al, 1998; Makrides et al, 1998; Owen et al, 
1981) may not be true as 55% of the infants in the present study were iron deficient. In addition, 
Lonnerdal and Hemell (1994) demonstrated that infants fed low iron formula became anaemic by 4 
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- 6 months and required early intervention to treat the problem. The iron content of breast milk 
may be of higher bioavailability then the iron found in humanized formulas but the absolute content 
is still relatively low. The infants in the L6nnerdal and Herne!! (1994) study who received the higher 
iron formula (4- 7 mg iron per litre; 2.6-5.6 mg iron per day) from 1.5-6 months of age 
improved iron stores until solid foods could be introduced. The breast fed infants receiving placebo 
in our study did not reach this level of iron intake until 6-months of age (Appendix A). Contrary to 
our findings, Ziegler and associates did not see any benefit supplementing breast fed infants with 
7.0 mg of iron per day between 1 -5.5 months. They did state that iron status in breastfed infants 
is not universally good (Ziegler, 2001 ). There has been agreement in the literature that less than 
1 0 mg of iron per day is enough to maintain iron status in formula fed infants (Walter, 1998; 
L6nnerdal and Herne!!, 1994). The poor iron status of the placebo infants of this study lend support 
to opinion that mild iron supplementation of breast fed infants until iron containing solids are 
introduced may be prudent to prevent ID (Ziegler, 2001; Fomon, 2001 ). Makrides and associates 
(1998) recommend high iron weaning foods as the solution to improving iron status, but points out 
there are infants who still receive no solids by 6 months. 
Given the rates of ID and IDA seen in this study the case is stronger to either supplement 
breast-fed infants during the first 6 months of life or to develop a screening regiment appropriate to 
identify infants who may become anaemic by 6 months. Only 4 of 20 infants in the supplemented 
group developed ID by 6 months compared to 11 of 20 in the group receiving no iron. There was 
no difference in the prevalence of IDA, 2 of 20 in placebo group compared to 1 of 20 in the 
supplemented group. These values are similar to others in Canada for the breast-feeding 
population (Innis et al, 1 997; Friel et al, 1 997). While no difference was seen between the plasma 
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ferritin concentrations of either group, the rate of ferritin decrease between 1 and 3.5 was 
significantly higher (ll139 1-lg/L (placebo) versus ll82 1-lg/L at 3.5 months). The higher incidence 
of 10 coupled with a high rate of iron store depletion are warning signs that this group are at a high 
risk for developing anaemia by 6-months. Since it has not been clarified what level of iron 
deficiency is detrimental to the cognitive and psychomotor development of infants it is of concern 
that such a high number of infants are suffering from this deficiency early but are left untreated until 
anaemia manifests itself. 
4.2.4 Potential Adverse Effects of Iron Supplementation 
4.2.4.1 Evidence of Oxidant Stress 
Potential oxidative stress was measured by any differences in antioxidant response, as a 
function of plasma FRAP value, RBC catalase and SOD. Iron supplementation at 7.5 mg iron per 
day does not appear to cause any oxidative stress to the treated infants compared to those not 
receiving iron. 
The plasma FRAP values, which measures the total antioxidant capacity of the infants' 
plasma showed no differences between groups. Theoretically, the infants that were under stress 
would demonstrate a lower value as there should be a decrease in non-enzymatic reducing factors 
in the plasma corresponding to the increased oxidation. The plasma FRAP values were within the 
range of healthy adults (Benzie and Strain, 1996) but more consistent with respect to elderly 
women (Cao et al, 1998) opposed to the 25-year old male standard, which was used throughout 
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this study. This is the first reported use of the assay on an infant population. Investigation of 
differences between sick infants under oxygen stress and healthy infants would be beneficial. 
There were no differences observed between the RBC catalase and SOD activities of the 
two groups. During peak supplementation (3.5 months) the catalase and SOD activities were 
virtually identical. There are few reports of the activity of the antioxidant enzymes in the infant 
population but the data is similar to that previously reported (Friel et al, 1997; van Zoeren-Grobben 
et al, 1997; Silvers et al, 1998; Friel et al, 2000). It has been shown that human plasma is 
susceptible to oxidative damage via a ferrous iron -hydrogen peroxide mechanism (Agil et al, 
1995). However no difference was detected in any of the measures of antioxidant response 
examined in the present study, which can be interpreted as iron supplementation at 7.5 mg per day 
does not put an infant at increase oxidative risk. It should be noted that the predictive value of this 
data is weak due to the low statistical power. A much larger sample size is needed for this type of 
enzyme analysis, far beyond the ability of this study. The FRAP assay appears to be a better 
suited test of oxidative stress for smaller groups. 
Analysis of problems associated with taking the supplement also showed no difference 
between the groups (Appendix B). These results provide answers to the common public 
perceptions that iron will cause fussiness, constipation and stomach cramps. There has been 
some indication that iron supplementation will have adverse effects on weight gain in young 
children (ldjradinata, 1994). Our data indicate that infants 0- 6 months receiving 7.5 mg iron/day 
do not have growth rates compromised. ldjradinata's study examined 12- 18 month infants using 
iron at 3.0-mg/kg-body weight, somewhat higher than is commonly accepted as the upper limit of 
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normal dietary supplementation, 2.5-3.12 mg/100 kcal (ldjradinata, 1994) versus 1.8-2.0 
mg/100 kcal (Fomon, 1993). 
4.2.4.2 Plasma Mineral Concentrations 
Plasma zinc and copper concentrations did not differ as a function of treatment or placebo. 
The plasma zinc and copper concentration were consistent with values previously reported by 
other researchers (Walravens et al, 1976; Hambidge et al, 1979; Gibson et al, 1981 ; Friel et al, 
1997). There was however an increase in the mean plasma zinc concentrations of the 
supplemented group between the 3.5 and 6 month blood sample. Given that not all infants 
completed the entire protocol of supplement between 3.5 and 6 months there are several 
possibilities which could cause this rise in plasma Zn in the supplemented group: a) inherent 
increase in zinc absorption caused the increase in plasma zinc due to the cessation of iron 
supplements, b) dietary intake between groups differed resulting in a higher mean zinc intake and 
consequently higher plasma zinc concentrations, c) another factor or combination of factors 
beyond the scope of this investigation played a part in the increased zinc absorption between 3.5 
and 6 months. 
It has been shown that iron supplements without zinc added could reduce zinc absorption 
by close to 50% as well as reduces the plasma zinc concentration in pregnant women (O'Brien, 
2000). However, the plasma zinc concentrations compared well with infants from the sample 
geographic area (Walravens et al, 1976; Hambidge et al, 1979). No difference was seen between 
the mean dietary zinc intakes of the supplemented group compared to the placebo group. We 
were unable to elucidate the cause of this rise in plasma zinc concentrations. There would appear 
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to be an interaction occurring with plasma zinc that requires further investigation and this study was 
not equipped to answer that particular question. 
4.3 Clinical Significance 
Our findings appear to support the recommendations of Fomon (2001 ), which call for the 
supplementation of breast-fed infants. While wide spread supplementation is an issue which 
should be approached with caution we have demonstrated that there is a need to further develop 
the screen procedures and predictors of infant iron status. Further investigation into the use of 
early haematological data and rate of iron store depletion should be undertaken to help clinicians 
accurately identify infants at risk of ID and IDA. Our data also show that infants in the first six 
months of life whom are exclusively breastfed are at increased risk of developing ID or IDA by six 
months in contrast to others have reported. While the choice to breast-feed is the healthiest choice 
for mothers to make for their infants, precautions with respect to iron nutrition should be taken and 
promoted. Whether these infants are screened more closely than the infants whom are formula fed 
or the breastfed infants are supplemented with iron during the first 4 - 6 months, it does appear that 
intervention is warranted. Mild iron supplementation does not appear to have any deleterious 
effects for the infants and is safe to give at the level used in this study. The question of zinc 
absorption could be addressed by adding zinc to the iron supplement (O'Brien et al, 2000; Fomon, 
2001). Given the possible cognitive and psychomotor effects iron deficiency can have on infants, 
improved screen or supplementation appears to be a reasonable course of action. 
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Chapter 5: Conclusion 
There are a number of risks associated with an infant depleting its iron stores to the point 
of nutritional deficiency. The literature points to the possibility of irreversible damage to the CNS, 
cognitive and psychomotor developmental delays and anaemia as the most severe and common 
effects of this deficiency. Given that each of these conditions would occur within the first year of 
life there is a small window of prevention time that must be seized if these effects are to be 
avoided. There are a number of conclusions, which can be drawn from the data presented within 
this thesis, which are listed below: 
1. The concentration of iron in human breast milk appears to be consistent with the 
lower ranges reported by other researchers. The iron concentrations of human 
breast milk decline significantly between 1 and 3.5 months of lactation. 
2. The direct method for GFAAS determination of human breast milk iron 
concentration described in the present study appears to be validated as a simple 
accurate and reliable procedure. 
3. Maternal haemoglobin at delivery is neither a predictor of human breast milk iron 
concentrations nor of infant 1-month iron status as measured by haemoglobin 
concentration. 
4. Mild iron supplementation at 7.5 mg per day for exclusively breast fed infants will 
promote a more healthy iron status compared to those exclusively breast fed 
infants not receiving supplemental iron. Mean haemoglobin, hematocrit and MCV 
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are improved, ferritin stores decline at a slower rate and incidence of iron 
deficiency is lower at six months in the supplemented infants compared to the 
infants receiving a placebo. 
5. Infant 1-month haemoglobin and the rate of decline in plasma ferritin concentration 
between a 1 and 3.5-month blood sample may provide a useful tool to predict 
breast-fed infant ferritin concentration at 6 months. 
6. Antioxidant status in blood, as defined by the infant erythrocyte catalase and 
superoxide dismutase activities and the plasma FRAP value, does not indicate 
that the iron is causing in vivo oxidative damage. Activities of antioxidant enzymes 
and the plasma FRAP value were in the expected ranges. 
7. There is an increased free radical generating potential, for those infants who have 
received supplemental iron in fecal samples collected at 6-months, as measured 
by the production of methanesulfinic acid production. Nothing is known as to the 
effect of the free radical production in the infant gastrointestinal tract. 
8. No difference was detected between the plasma copper concentrations of infants 
receiving supplements and those receiving the placebo. All values were within the 
expected range for the subjects. There was however a significant rise between 
the 3.5 month and 6 month plasma zinc concentrations of the supplemented 
infants, which could not be explained by dietary analysis. 
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Appendix A 
Table 6.1 Dietary Composition Reported by Three Day Diet Record- Supplemented Infants 
3-Day Diet Record Summary 
Specific Nutritional Composition and Nutrients Recorded as Mean (+/· Standard Deviation) Daily Intake 
Iron Sup lemented Group (N = 16) 
Age Energy Protein (g) Fat (g) Carbohydrate Fe (mg) Cu (mg) Zn (mg) Se (~g) Ascorbic Acid (Kcals) (g) (mg) 
1-Month 525 (0) 9 (0) 33 (0) 57 (0) 0.3 (0) 0.3 (0) 2.4 (0) 10.5 (0) 30 (0) 
3.5-Month 526 (29) 9 (1) 32 (3) 58 (3) 1.5 (2.9) 0.3 (0.03) 2.6 (0.3) 9.3 (3.2) 31 (3) 
6-Month 632 (121) 14 (4) 32 (6) 78 (16) 7.8 (5.6) 0.5 (0.15) 3.8 (1 .5) 12.9 (5.7) 48 (15) 
Table 6.2 Dietary Composition Reported by Three Day Diet Record- Placebo Infants 
3-Day Diet Record Summary 
Specific Nutritional Composition and Nutrients Recorded as Mean (+/· Standard Deviation) Daily Intake 
Placebo Group ~N = 17~ 
Age Energy Protein Fat Carbohydrate Fe Cu Zn Se Ascorbic Acid (Kcals) ~~) !~) !~) (m~! (m~~ (mg~ ~~~~ !m~~ 
1-Month 525 (0) 9 (0) 33 (0) 57 (0) 0.3 (0) 0.3 (0) 2.4 (0) 10.5 (0) 30 (0) 
3.5-Month 519 (35) 9 (1) 32 (2) 56 (4) 0.4 (0.2) 0.3 (0) 2.4 (0.1) 10.4 (0.3) 30 (2) 
6-Month 667(113) 14 (3) 35 (6) 81 (15) 8.5 (6.3) 0.5 (0.1) 3.7 (1 .0) 13.3 (4.8) 48 (1 5) 
111 
Appendix 8 
Table 6.3. Reported Problems/Discomfort With Taking Medication 
Symptom Supplemented Group Placebo Group Reported % of Infants Reported % of Infants 
No Problem 16/38 42 20/32 63 
Gas 11/38 29 9/32 28 
Constipation 13/38 34 6/32 19 
c~~ ~~ 5 w~ o 
Spit-up 4/38 11 3/32 9 
Blood in Stool 1/38 3 0/32 0 
Diarrhea 1/38 3 0/32 0 
No statistical difference in problems encountered between groups by Fisher exact test (p>0.05). 
Table 6.4. Problems/Discomfort Reporting Options 
Option # Description Option # Description 
0 No Problem 8 Constipation, Spit-up 
1 Gas 9 Spit-up, Constipation 
2 Constipation 10 Constipation, Gas 
3 Gas, Constipation 11 Blood in Stool 
4 Cramps 12 Gas, Cramps, Constipation 
5 Spit-up 13 Gas, Cramps, Spit-up 
6 Gas, Spit-up 14 Diarrhea 
7 Gas, Cramps 
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Appendix C 
DEPARTMENT OF BIOCHEMISTRY 
MEMORIAL UNIVERSITY OF NEWFOUNDLAND 
ST. JOHN'S, NEWFOUNDLAND, A 18 3X9 
CONSENT TO PARTICIPATE IN RESEARCH 
TITLE: IRON SUPPLEMENTATION OF HUMAN MILK FED FULL-TERM INFANTS 
INVESTIGATORS: Drs. James Friel, Wayne Andrews, Khalid Aziz, 
Drs. Mary Courage, Russell Adams, Poh Gin Kwa 
You and your child have been asked to participate in a research project. Participation in the study is entirely 
voluntary. You may decide not to participate or you may decide to withdraw from the study at any time without 
affecting your normal treatment. Confidentiality of information concerning participants will be maintained by the 
investigators. The investigator(s) will be available during the study should you have any problems or questions about 
the study. 
Below is a list of points which provide information about the study and what will be expected of you and your child 
should you decide to participate. 
1. PURPOSE: We plan to compare the iron levels of breast-fed infants who 
have been provided with either an iron supplement or a placebo. Iron is an essential element for all of us and we want 
to ascertain that breast-fed infants are receiving a sufficient amount of it. We are also interested in cognition (learning, 
thinking, remembering), and language. Certain of these abilities may develop at a different rate depending on whether 
or not infants receive enough iron in early life. How much iron is needed in unknown. For this study, a breast-fed 
infant is someone who has received most of his/her food intake as breast-milk for a period of at least four months, 
preferably for six months. 
2. DESCRIPTION OF PROCEDURES AND TESTS: All infants will be divided into two equal sized groups. One group 
will receive the iron supplement and the other the placebo. None of the Doctors involved will know into which group 
your infant is placed. In this manner all infants will be treated equally and the results will not be influenced by prior 
knowledge of group placement. For each infant in the study, we wish to take a small blood sample (about half a 
teaspoon) from your infant four times, once each at 1,3 ~. 6 and 12 months of age. This blood sample will be 
collected by Dr. Andrews, Dr. Aziz or their delegate who is experienced in this procedure. At 12 months, we wish to 
administer two tests of infant development. These will be conducted by psychologists who are well trained in these 
procedures. You will be asked to attend our Infant Nutrition Clinic at these times and to fill out a 3-day, dietary record 
of what your child eats and drinks, before you come to the clinic. You will also be asked to bring a stool sample in a 
plastic bag which we will supply to the 1 and 3 ~month clinics and also to bring a 5 mi. (1 tsp.) breast milk sample to 
these clinics as well. We will ask you to supply a dietary record for the infant at 9 months of age although there will be 
no clinic visit at this time. 
3. DURATION OF THE PROJECT: The project will last for 12 months. 
4. FORESEEABLE RISKS, DISCOMFORTS, OR INCONVENIENCES: None of the developmental tests that are 
described above involve any risks or discomforts to your child. The only inconvenience involved is that if you live in 
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the St. John's area you will have to bring your child to Memorial University for testing at 12 months after he or she 
leaves the hospital. However, we will provide convenient, free parking. Also, we will ask you to fill out three day 
dietary records at 1, 3 ~. 6, 9 and 12 months of age. The only discomfort to your baby will be blood collection on four 
occasions. 
5. BENEFITS TO YOU. The main benefit of participation is that you will be given a regular and immediate progress 
report on your child's development and also their iron status. If your child's development is below the norm for his or 
her age group in any way, you will know about it right away and can consult your family doctor for further referral. 
Early discovery of many problems can result in a better outcome. 
6. ALTERNATIVE TREATMENT IF YOU DECIDE NOT TO PARTICIPATE: If you decide not to participate in this 
project, you can still have your child's developmental progress assessed by your family doctor or referral to other 
health care professionals. You may also wish to consult your family doctor about over the counter iron 
supplementation. 
Finally, your signature on this form indicates that you have understood to your satisfaction the information 
regarding your participation in the research project and agree to participate as a subject. In no way does this waive 
your legal rights nor release the Investigators, sponsors, or involved institutions from their legal and professional 
responsibilities. 
I, --------------------------------------------, the undersigned, agree to my participation and to the participation 
of ------------------------------------------ my child or ward in the research project described. 
Any questions have been answered and I understand what is involved in the study. I realize that participation is 
voluntary and that I can withdraw my participation at any time, and that there is no guarantee that I will benefit from 
my involvement. I acknowledge that a copy of this form has been given to me. 
Signatures of ParenUGuardian of Participant Date 
Signatures of witness Date 
To be signed by investigator: 
To the best of my ability I have fully explained to the subject the nature of this research project. I have invited 
questions and provided answers. I believe that the subject fully understands the implications and voluntary nature of 
the study. 
Signature of the Investigator Date 
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Appendix D 
Breastfeeding Iron Study- Parent Introduction 
How long do you plan to Breastfed? 
This is a voluntary study in which we (Memorial University with the cooperation of the 
neonatologists at the Janeway, and Dr. Kwa at the Grace), are looking at whether Breastfed infants 
are receiving enough iron from Mother's milk. Iron is very important for growth, including brain 
functioning in the infant and all of us. We do not know at this time how much is needed. 
Infants are placed in two groups: 
1. One group will receive cherry syrup containing iron, 
2. One group will receive cherry syrup with no iron. 
Only the pharmacist preparing the study medication will know which babies are in the individual 
groups. We would like for you to attend the clinic at the Janeway where we will: 
1. Weigh the baby 
2. Take measurements of HT. and HC. 
3. Take a small blood sample to check the iron content of the blood. 
1 ml of blood is taken only 4 times at: 
1 month 
31/2 months 
6 months 
12 months 
At 12 months we would like to perform a developmental assessment of your child and that will tell 
us how they are progressing through normal development of learning, language development, 
behavior, & motor skills. 
Your part in the study: 
1. Three days before you bring your baby to the JCHC clinic, keep a record of what the baby 
feeds. So, for the first 4 months record the time and duration of Breastfeeding. After that time if 
you decide to introduce rice cereal, you would also record the amount and time. 
2. We require 1 tsp of expressed breastmilk and a small stool sample of the baby. We will send 
the containers for these samples to you. 
The clinics are at the JCHC and generally there is no waiting. We allow an appointment time of 45 
minutes for each visit. Subsequent visits are usually a lot faster. 
We are happy to provide compensation for: 
1. Parking meters 
2. Mileage allowance for gas 
3. Taxi - should you require transportation. 
You may also bring your other children if you need to. 
You will also receive final results of the study. 
I would like to call you again tomorrow to answer any questions and receive your answer. 
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June 20, 2001 
Dear: 
Memorial University of Newfoundland 
Department of Biochemistry 
St. John's, NF, Canada 
A1B 3X9 
I hope that all is well with you and your family. 
We are requesting a three day dietary record from the mothers of the babies who participated in 
the Iron Supplementation Study. We would really appreciate it if you would take the time to 
complete this record and mail it in the self addressed envelope enclosed. 
Thank you for you continued interest in our research. It is much appreciated. 
All the Best, 
Allison McDonald R.N. 
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Family Doctor Information Letter 
July 28,1999 
Dear Dr. _______ _ 
____________ son/daughter of ___________ _ 
is a participant in the Research Project entitled "The Iron Supplementation of Human Milk Fed 
Full Term Infants." The subjects in this study are randomized into one of two groups of which 
one group receives an iron supplement and the other a placebo. Please do not prescribe any iron 
preparation for this infant without first contacting Dr. Wayne Andrews or Dr. Khalid Aziz at the 
Janeway Child Health Centre. The telephone number is 778-4622. 
For your information we are enclosing a copy of a study which shows that Iron does not cause 
constipation. Thank you very much for your cooperation. 
Very truly yours, 
Dr. James K. Friel 
Dr. Wayne Andrews 
Dr. Khalid Aziz 
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Appendix E 
Fecal Iron and Free Radical Production -Pilot Study 
Fecal iron and free radical generating potential was measured to establish whether the 
supplemented infants have an increased free radical generating system in the gastrointestinal tract 
due to the higher concentration of iron passing through in the fecal materials. Iron concentrations 
were determined in 1 and 3.5-month stool samples to establish a baseline and peak 
supplementation iron concentration in the fecal material. The free radical generating capacity was 
determined using the methanesulfinic acid assay for hydroxyl radical generation. Due to 
insufficient amounts of fecal samples at 3.5-months it was not possible to obtain a value of 
methanesulfinic acid at this point. Therefore, methanesulfinic acid was only determined at 1 and 6 
months. This makes the direct comparison between the fecal sample iron and methanesulfinic 
acid production impossible. 
Iron was determined in a total of 20-paired fecal samples using FAAS at both 1 and 3.5-
months. The methanesulfinic acid assay was carried out on 7 samples from the above noted 20 
samples. The data are summarized in Table E1 and the relationships between methanesulfinic 
acid are shown in figure E.1 and fecal iron concentrations in figure E.2. 
There was a higher level of methanesulfinic acid produced in the stool collected from 
infants at 6 months who had been receiving the iron supplement. This rise indicates the 
supplemental iron leads to increased free radical production in the feces as it passes through the 
colon. These findings are in keeping with data collected from iron-supplemented adults in the UK 
(Lund et al, 1999). Since no elevation was seen in the antioxidant defences and no decreases 
were observed in the FRAP values there does not appear to be any harm caused by this increase 
in free radical generation. Animal studies focusing on fecal MSA would be beneficial to elucidate 
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the actual effects on the colon and the rest of gastrointestinal tract compared to the responses of 
the antioxidant defence systems. 
Table 6.5. Iron Content and Methanesulfinic Acid Production of Fecal Samples 
Age 
N 
1 Month 
3.5 Month 
6 Month 
Supplemented Group 
Iron Methanesulfinic Acid 
(mg/g dry feces) (mM/g wet feces) 
11 3 
0.14 (0.09) 0.13 (0.06) 
1.32 (1 .04) 
0.46 (0.03) 
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Placebo Group 
Iron 
(mg/g dry feces) 
9 
0.15 (0.13) 
0.36 (0.72) 
Methanesulfinic Acid 
(mM/g wet feces) 
4 
0.25 (0.12) 
0.10 (0.06) 
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Figure 6.1 Methanesulfinic acid production from infant stool samples collected at 1 and 6 month clinic visits. 
Methanesulfinic acid is a measure of free radical generation. Mean +/- SD (error bars). t indicates difference between 
times within group; p<0.05. t indicates difference between groups at same time; p<0.05. 
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Figure 6.2 Fecal iron concentrations measured at 1 and 3.5-months. t denotes significant difference between time points 
within groups. t denotes significant difference between group within particular time point. 
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